BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. [PMID: 15758010 DOI: 10.1056/nejmoa043331] [Cited by in Crossref: 4335] [Cited by in F6Publishing: 2203] [Article Influence: 255.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim HR, Lee JJ, Lee JI, Nam DH, Suh YL, Seol HJ. Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases. J Korean Neurosurg Soc 2016;59:44-51. [PMID: 26885285 DOI: 10.3340/jkns.2016.59.1.44] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Song HR, Gonzalez-Gomez I, Suh GS, Commins DL, Sposto R, Gilles FH, Deneen B, Erdreich-Epstein A. Nuclear factor IA is expressed in astrocytomas and is associated with improved survival. Neuro Oncol 2010;12:122-32. [PMID: 20150379 DOI: 10.1093/neuonc/nop044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
3 Wu Y, Liang S, Xu B, Zhang R, Zhu M, Zhou W, Zhang S, Guo J, Xu L, Zhu H. Long noncoding RNA eosinophil granule ontogeny transcript inhibits cell proliferation and migration and promotes cell apoptosis in human glioma. Exp Ther Med 2017;14:3817-23. [PMID: 29042985 DOI: 10.3892/etm.2017.4949] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22:iv1-iv96. [PMID: 33123732 DOI: 10.1093/neuonc/noaa200] [Cited by in Crossref: 111] [Cited by in F6Publishing: 124] [Article Influence: 111.0] [Reference Citation Analysis]
5 Jin D, Tran N, Thomas N, Tran DD. Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity. PLoS One 2019;14:e0223555. [PMID: 31600301 DOI: 10.1371/journal.pone.0223555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Umehara T, Arita H, Yoshioka E, Shofuda T, Kanematsu D, Kinoshita M, Kodama Y, Mano M, Kagawa N, Fujimoto Y, Okita Y, Nonaka M, Nakajo K, Uda T, Tsuyuguchi N, Fukai J, Fujita K, Sakamoto D, Mori K, Kishima H, Kanemura Y. Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathol Commun 2019;7:99. [PMID: 31215469 DOI: 10.1186/s40478-019-0749-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
7 Mijnes J, Veeck J, Gaisa NT, Burghardt E, de Ruijter TC, Gostek S, Dahl E, Pfister D, Schmid SC, Knüchel R, Rose M. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer. Clin Epigenetics 2018;10:15. [PMID: 29445424 DOI: 10.1186/s13148-018-0447-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
8 Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome. Endocr Pathol 2010;21:227-9. [PMID: 21061089 DOI: 10.1007/s12022-010-9138-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
9 Yan C, Wang J, Yang Y, Ma W, Chen X. Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma. J Cell Mol Med 2019;23:4876-82. [PMID: 31210419 DOI: 10.1111/jcmm.14417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Barthel FP, Johnson KC, Wesseling P, Verhaak RGW. Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. Neurol Clin 2018;36:421-37. [PMID: 30072063 DOI: 10.1016/j.ncl.2018.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
11 Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World J Surg Oncol 2013;11:284. [PMID: 24160898 DOI: 10.1186/1477-7819-11-284] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
12 Ly KI, Oakley DH, Pine AB, Frosch MP, Chiou SH, Betensky RA, Pomerantz SR, Hochberg FH, Batchelor TT, Cahill DP, Dietrich J. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. Oncologist 2019;24:402-13. [PMID: 30097523 DOI: 10.1634/theoncologist.2018-0086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Butta S, Gupta MK. Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival. Med Pharm Rep 2021;94:318-24. [PMID: 34430853 DOI: 10.15386/mpr-1951] [Reference Citation Analysis]
14 Han J, Puri RK. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. J Neurooncol 2018;136:463-74. [PMID: 29168083 DOI: 10.1007/s11060-017-2680-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
15 De Waele J, Verhezen T, van der Heijden S, Berneman ZN, Peeters M, Lardon F, Wouters A, Smits ELJM. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. J Exp Clin Cancer Res 2021;40:213. [PMID: 34172082 DOI: 10.1186/s13046-021-02017-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Allingham-Hawkins D, Lea A, Levine S. DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform. PLoS Curr 2010;2:RRN1186. [PMID: 20972474 DOI: 10.1371/currents.RRN1186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Humphreys LM, Smith P, Chen Z, Fouad S, D'Angiolella V. The role of E3 ubiquitin ligases in the development and progression of glioblastoma. Cell Death Differ 2021;28:522-37. [PMID: 33432111 DOI: 10.1038/s41418-020-00696-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Otto-Meyer S, DeFaccio R, Dussold C, Ladomersky E, Zhai L, Lauing KL, Bollu LR, Amidei C, Lukas RV, Scholtens DM, Wainwright DA. A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors. Brain Behav Immun Health 2020;2:100025. [PMID: 32190845 DOI: 10.1016/j.bbih.2019.100025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
19 Paech D, Dreher C, Regnery S, Meissner JE, Goerke S, Windschuh J, Oberhollenzer J, Schultheiss M, Deike-Hofmann K, Bickelhaupt S, Radbruch A, Zaiss M, Unterberg A, Wick W, Bendszus M, Bachert P, Ladd ME, Schlemmer HP. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. Eur Radiol 2019;29:4957-67. [PMID: 30809720 DOI: 10.1007/s00330-019-06066-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
20 Molitoris JK, Rao YJ, Patel RA, Kane LT, Badiyan SN, Gittleman H, Barnholtz-Sloan JS, Bentzen SM, Kruser TJ, Huang J, Mehta MP. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. J Neurooncol 2017;134:331-8. [PMID: 28643151 DOI: 10.1007/s11060-017-2529-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
21 Nieto-Sampedro M, Valle-Argos B, Gómez-Nicola D, Fernández-Mayoralas A, Nieto-Díaz M. Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol. 2011;5:265-314. [PMID: 22084619 DOI: 10.4137/cmo.s7685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
22 Shabihkhani M, Telesca D, Movassaghi M, Naeini YB, Naeini KM, Hojat SA, Gupta D, Lucey GM, Ontiveros M, Wang MW, Hanna LS, Sanchez DE, Mareninov S, Khanlou N, Vinters HV, Bergsneider M, Nghiemphu PL, Lai A, Liau LM, Cloughesy TF, Yong WH. Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. J Neurooncol 2017;132:351-8. [PMID: 28161760 DOI: 10.1007/s11060-017-2377-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
23 Álvarez-Satta M, Matheu A. Primary cilium and glioblastoma. Ther Adv Med Oncol 2018;10:1758835918801169. [PMID: 30302130 DOI: 10.1177/1758835918801169] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
24 Berghoff AS, Stefanits H, Heinzl H, Preusser M. Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers. Clin Neuropathol 2012;31:206-9. [PMID: 22720693 DOI: 10.5414/np300511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Ridolfi C, Pasini G, Drudi F, Barzotti E, Santelmo C, Polselli A, Ravaioli A. Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report. J Med Case Rep 2013;7:29. [PMID: 23347560 DOI: 10.1186/1752-1947-7-29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
26 Bosnyák E, Michelhaugh SK, Klinger NV, Kamson DO, Barger GR, Mittal S, Juhász C. Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma. Clin Nucl Med 2017;42:341-7. [PMID: 28195901 DOI: 10.1097/RLU.0000000000001577] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
27 Rosager AM, Dahlrot RH, Sørensen MD, Bangsø JA, Hansen S, Kristensen BW. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. J Neuropathol Exp Neurol 2021:nlab124. [PMID: 34875075 DOI: 10.1093/jnen/nlab124] [Reference Citation Analysis]
28 Alrfaei BM, Clark P, Vemuganti R, Kuo JS. MicroRNA miR-100 Decreases Glioblastoma Growth by Targeting SMARCA5 and ErbB3 in Tumor-Initiating Cells. Technol Cancer Res Treat 2020;19:1533033820960748. [PMID: 32945237 DOI: 10.1177/1533033820960748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol 2012;14:1519-26. [PMID: 23099652 DOI: 10.1093/neuonc/nos265] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
30 Song J, Zhao D, Sun G, Yang J, Lv Z, Jiao B. PTPRM methylation induced by FN1 promotes the development of glioblastoma by activating STAT3 signalling. Pharm Biol 2021;59:904-11. [PMID: 34225581 DOI: 10.1080/13880209.2021.1944220] [Reference Citation Analysis]
31 Liu SJ, Yang ST, Chen SM, Huang YC, Lee WH, Ho J, Chen YC, Tseng YY. Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas. Ther Adv Med Oncol 2019;11:1758835919875555. [PMID: 31632467 DOI: 10.1177/1758835919875555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cai JJ, Qi ZX, Hua W, Zhu JJ, Zhang X, Yao Y, Mao Y. Increased expression of Capn4 is associated with the malignancy of human glioma. CNS Neurosci Ther 2014;20:521-7. [PMID: 24628706 DOI: 10.1111/cns.12248] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
33 Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol 2015;17:180-8. [PMID: 25165194 DOI: 10.1093/neuonc/nou154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
34 Sato Y, Kurose A, Ogawa A, Ogasawara K, Traganos F, Darzynkiewicz Z, Sawai T. Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. Cancer Biol Ther 2009;8:452-7. [PMID: 19305157 DOI: 10.4161/cbt.8.5.7740] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
35 Deb P, Mani NS, Sudumbrekar SM, Taneja N, Patrikar S. Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas. Med J Armed Forces India 2013;69:228-36. [PMID: 24600115 DOI: 10.1016/j.mjafi.2012.08.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Creemers SG, van Koetsveld PM, van den Dungen ES, Korpershoek E, van Kemenade FJ, Franssen GJ, de Herder WW, Feelders RA, Hofland LJ. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. J Clin Endocrinol Metab 2016;101:4574-84. [PMID: 27603910 DOI: 10.1210/jc.2016-2768] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
37 Shang E, Zhang Y, Shu C, Ishida CT, Bianchetti E, Westhoff MA, Karpel-Massler G, Siegelin MD. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci Rep 2018;8:15383. [PMID: 30337641 DOI: 10.1038/s41598-018-33784-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Balça-Silva J, Matias D, Do Carmo A, Dubois LG, Gonçalves AC, Girão H, Canedo NHS, Correia AH, De Souza JM, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto V. Glioblastoma entities express subtle differences in molecular composition and response to treatment. Oncol Rep 2017;38:1341-52. [PMID: 28714013 DOI: 10.3892/or.2017.5799] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
39 Cooper J, Giancotti FG. Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell 2019;35:347-67. [PMID: 30889378 DOI: 10.1016/j.ccell.2019.01.007] [Cited by in Crossref: 160] [Cited by in F6Publishing: 154] [Article Influence: 53.3] [Reference Citation Analysis]
40 Lim J, Park Y, Ahn JW, Hwang SJ, Kwon H, Sung KS, Cho K. Maximal surgical resection and adjuvant surgical technique to prolong the survival of adult patients with thalamic glioblastoma. PLoS One 2021;16:e0244325. [PMID: 33539351 DOI: 10.1371/journal.pone.0244325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Hervouet E, Lalier L, Debien E, Cheray M, Geairon A, Rogniaux H, Loussouarn D, Martin SA, Vallette FM, Cartron PF. Disruption of Dnmt1/PCNA/UHRF1 interactions promotes tumorigenesis from human and mice glial cells. PLoS One 2010;5:e11333. [PMID: 20613874 DOI: 10.1371/journal.pone.0011333] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 7.2] [Reference Citation Analysis]
42 Johnson DR, Sawyer AM, Meyers CA, O'Neill BP, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 2012;14:808-16. [PMID: 22508762 DOI: 10.1093/neuonc/nos082] [Cited by in Crossref: 69] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
43 Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell 2018;34:163-177.e7. [PMID: 29990498 DOI: 10.1016/j.ccell.2018.06.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 24.0] [Reference Citation Analysis]
44 Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. Clinically Relevant Imaging Features for MGMT Promoter Methylation in Multiple Glioblastoma Studies: A Systematic Review and Meta-Analysis. AJNR Am J Neuroradiol 2018;39:1439-45. [PMID: 30002055 DOI: 10.3174/ajnr.A5711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
45 Park JW, Turcan Ş. Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas. Cancers (Basel) 2019;11:E1616. [PMID: 31652645 DOI: 10.3390/cancers11101616] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
46 Dahlrot RH, Sørensen MD, Rosager AM, Hellwege S, Bangsø JA, Rosenberg T, Petterson SA, Klitkou J, Fosmark S, Hansen S, Kristensen BW. Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. CNS Oncol 2014;3:287-98. [PMID: 25286040 DOI: 10.2217/cns.14.30] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
47 Vellimana AK, Recinos VR, Hwang L, Fowers KD, Li KW, Zhang Y, Okonma S, Eberhart CG, Brem H, Tyler BM. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. J Neurooncol 2013;111:229-36. [PMID: 23224713 DOI: 10.1007/s11060-012-1014-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
48 Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018;20:iv1-iv86. [PMID: 30445539 DOI: 10.1093/neuonc/noy131] [Cited by in Crossref: 818] [Cited by in F6Publishing: 716] [Article Influence: 272.7] [Reference Citation Analysis]
49 Mills BN, Albert GP, Halterman MW. Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche. Cancer Microenviron 2017;10:57-68. [PMID: 28822081 DOI: 10.1007/s12307-017-0197-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
50 Matsuno A, Murakami M, Hoya K, Yamada SM, Miyamoto S, Yamada S, Son JH, Nishido H, Ide F, Nagashima H, Sugaya M, Hirohata T, Mizutani A, Okinaga H, Ishii Y, Tahara S, Teramoto A, Osamura RY. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. Med Mol Morphol 2014;47:1-7. [PMID: 23955641 DOI: 10.1007/s00795-013-0050-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
51 Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, Caballero OL, Westra WH, Sidransky D, Hoque MO. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2786-2794. [PMID: 18843024 DOI: 10.1158/1055-9965.epi-08-0192] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
52 Doan P, Musa A, Murugesan A, Sipilä V, Candeias NR, Emmert-Streib F, Ruusuvuori P, Granberg K, Yli-Harja O, Kandhavelu M. Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways. Cells 2020;9:E681. [PMID: 32164385 DOI: 10.3390/cells9030681] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
53 Buttarelli FR, Massimino M, Antonelli M, Lauriola L, Nozza P, Donofrio V, Arcella A, Oliva MA, Di Rocco C, Giangaspero F. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas. Childs Nerv Syst 2010;26:1051-6. [PMID: 20552207 DOI: 10.1007/s00381-010-1191-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
54 Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 2009;8:407-14. [PMID: 19174557 DOI: 10.1158/1535-7163.MCT-08-0854] [Cited by in Crossref: 70] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
55 Bernal Rubio YL, González-Reymúndez A, Wu KH, Griguer CE, Steibel JP, de Los Campos G, Doseff A, Gallo K, Vazquez AI. Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme. G3 (Bethesda) 2018;8:3627-36. [PMID: 30228192 DOI: 10.1534/g3.118.200391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
56 Hassanzadeh C, Rao YJ, Chundury A, Rowe J, Ponisio MR, Sharma A, Miller-Thomas M, Tsien CI, Ippolito JE. Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma. Front Oncol 2017;7:178. [PMID: 28868256 DOI: 10.3389/fonc.2017.00178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
57 Liu D, Chen J, Hu X, Yang K, Liu Y, Hu G, Ge H, Zhang W, Liu H. Imaging-Genomics in Glioblastoma: Combining Molecular and Imaging Signatures. Front Oncol 2021;11:699265. [PMID: 34295824 DOI: 10.3389/fonc.2021.699265] [Reference Citation Analysis]
58 Hsu CY, Ho HL, Lin SC, Chang-Chien YC, Chen MH, Hsu SP, Yen YS, Guo WY, Ho DM. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product. J Neurooncol 2015;122:179-88. [PMID: 25575938 DOI: 10.1007/s11060-014-1701-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
59 Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8:a019505. [PMID: 27194046 DOI: 10.1101/cshperspect.a019505] [Cited by in Crossref: 371] [Cited by in F6Publishing: 318] [Article Influence: 61.8] [Reference Citation Analysis]
60 Priesterbach-Ackley LP, Boldt HB, Petersen JK, Bervoets N, Scheie D, Ulhøi BP, Gardberg M, Brännström T, Torp SH, Aronica E, Küsters B, den Dunnen WFA, de Vos FYFL, Wesseling P, de Leng WWJ, Kristensen BW. Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. Neuropathol Appl Neurobiol 2020;46:478-92. [PMID: 32072658 DOI: 10.1111/nan.12610] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
61 Jovčevska I. Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma. Front Oncol 2020;10:798. [PMID: 32500035 DOI: 10.3389/fonc.2020.00798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
62 Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer 2019;19:968. [PMID: 31623593 DOI: 10.1186/s12885-019-6177-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
63 Berghoff AS, Hainfellner JA, Marosi C, Preusser M. Assessing MGMT methylation status and its current impact on treatment in glioblastoma. CNS Oncol 2015;4:47-52. [PMID: 25586425 DOI: 10.2217/cns.14.50] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
64 García M, Clopés A, Bruna J, Martínez M, Fort E, Gil M. Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Manag Res 2009;1:137-50. [PMID: 21188132 DOI: 10.2147/cmr.s5598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
65 Wang H, Shi L, Wang Z. A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma. Front Oncol 2021;11:756817. [PMID: 34804949 DOI: 10.3389/fonc.2021.756817] [Reference Citation Analysis]
66 Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, Winkler F. Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol 2016;18:315-28. [PMID: 26459812 DOI: 10.1093/neuonc/nov180] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
67 Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, Quiñones-Hinojosa A. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114:587-94. [PMID: 20887095 DOI: 10.3171/2010.8.JNS1081] [Cited by in Crossref: 107] [Cited by in F6Publishing: 52] [Article Influence: 8.9] [Reference Citation Analysis]
68 Decavèle M, Weiss N, Rivals I, Prodanovic H, Idbaih A, Mayaux J, Similowski T, Demoule A. Prognosis of patients with primary malignant brain tumors admitted to the intensive care unit: a two-decade experience. J Neurol 2017;264:2303-12. [PMID: 28993874 DOI: 10.1007/s00415-017-8624-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
69 Marchi F, Sahnane N, Cerutti R, Cipriani D, Barizzi J, Stefanini FM, Epistolio S, Cerati M, Balbi S, Mazzucchelli L, Sessa F, Pesce GA, Reinert M, Frattini M. The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation. Front Oncol 2019;9:1569. [PMID: 32039032 DOI: 10.3389/fonc.2019.01569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
70 Bralten LB, French PJ. Genetic alterations in glioma. Cancers (Basel) 2011;3:1129-40. [PMID: 24212656 DOI: 10.3390/cancers3011129] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
71 Kraus TF, Kolck G, Greiner A, Schierl K, Guibourt V, Kretzschmar HA. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma. Tumour Biol 2015;36:8439-46. [PMID: 26022161 DOI: 10.1007/s13277-015-3606-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
72 Zhou X, Li G, An S, Li WX, Yang H, Guo Y, Dai Z, Dai S, Zheng J, Huang J, Iavarone A, Zhao X. A new method of identifying glioblastoma subtypes and creation of corresponding animal models. Oncogene 2018;37:4781-91. [PMID: 29769617 DOI: 10.1038/s41388-018-0305-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Palanca-Ballester C, Rodriguez-Casanova A, Torres S, Calabuig-Fariñas S, Exposito F, Serrano D, Redin E, Valencia K, Jantus-Lewintre E, Diaz-Lagares A, Montuenga L, Sandoval J, Calvo A. Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers (Basel) 2021;13:3016. [PMID: 34208598 DOI: 10.3390/cancers13123016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol. 2010;177:1491-1502. [PMID: 20671264 DOI: 10.2353/ajpath.2010.091021] [Cited by in Crossref: 221] [Cited by in F6Publishing: 211] [Article Influence: 18.4] [Reference Citation Analysis]
75 Lohkamp LN, Schinz M, Gehlhaar C, Guse K, Thomale UW, Vajkoczy P, Heppner FL, Koch A. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. PLoS One 2016;11:e0156422. [PMID: 27253461 DOI: 10.1371/journal.pone.0156422] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
76 Tang X, Xu P, Chen A, Deng G, Zhang S, Gao L, Dai L, Chen Q. Prognostic and Predictive Value of an Immunoscore Signature in Glioblastoma Multiform. Front Genet 2020;11:514363. [PMID: 33244317 DOI: 10.3389/fgene.2020.514363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer 2011;10:128. [PMID: 21988793 DOI: 10.1186/1476-4598-10-128] [Cited by in Crossref: 200] [Cited by in F6Publishing: 187] [Article Influence: 18.2] [Reference Citation Analysis]
78 Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol 2015;47:417-28. [PMID: 26035292 DOI: 10.3892/ijo.2015.3026] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
79 Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18:170-86. [PMID: 33293629 DOI: 10.1038/s41571-020-00447-z] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 32.0] [Reference Citation Analysis]
80 Johannessen TC, Prestegarden L, Grudic A, Hegi ME, Tysnes BB, Bjerkvig R. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Neuro Oncol 2013;15:269-78. [PMID: 23258843 DOI: 10.1093/neuonc/nos301] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
81 Morandi L, Franceschi E, de Biase D, Marucci G, Tosoni A, Ermani M, Pession A, Tallini G, Brandes A. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. BMC Cancer 2010;10:48. [PMID: 20167086 DOI: 10.1186/1471-2407-10-48] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
82 Michael AP, Watson VL, Ryan D, Delfino KR, Bekker SV, Cozzens JW. Effects of 5-ALA dose on resection of glioblastoma. J Neurooncol 2019;141:523-31. [PMID: 30644009 DOI: 10.1007/s11060-019-03100-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
83 Zhao N, Wang F, Ahmed S, Liu K, Zhang C, Cathcart SJ, DiMaio DJ, Punsoni M, Guan B, Zhou P, Wang S, Batra SK, Bronich T, Hei TK, Lin C, Zhang C. Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma. Front Oncol 2021;11:616625. [PMID: 34094902 DOI: 10.3389/fonc.2021.616625] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Inno A, Fanetti G, Bartolomeo MD, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, Braud F, Bossi I, Pietrantonio F. Role of MGMT as biomarker in colorectal cancer. World J Clin Cases 2014; 2(12): 835-839 [PMID: 25516857 DOI: 10.12998/wjcc.v2.i12.835] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
85 Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. Target Oncol 2016;11:337-43. [PMID: 26538496 DOI: 10.1007/s11523-015-0397-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
86 Mesti T, Ocvirk J. Malignant gliomas: old and new systemic treatment approaches. Radiol Oncol 2016;50:129-38. [PMID: 27247544 DOI: 10.1515/raon-2015-0003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
87 Nagarajan RP, Costello JF. Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 2009;6:436-46. [PMID: 19560734 DOI: 10.1016/j.nurt.2009.04.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
88 Wager M, Menei P, Guilhot J, Levillain P, Michalak S, Bataille B, Blanc JL, Lapierre F, Rigoard P, Milin S, Duthe F, Bonneau D, Larsen CJ, Karayan-Tapon L. Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer 2008;98:1830-8. [PMID: 18506188 DOI: 10.1038/sj.bjc.6604378] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
89 Shao H, Chung J, Lee K, Balaj L, Min C, Carter BS, Hochberg FH, Breakefield XO, Lee H, Weissleder R. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun 2015;6:6999. [PMID: 25959588 DOI: 10.1038/ncomms7999] [Cited by in Crossref: 313] [Cited by in F6Publishing: 301] [Article Influence: 44.7] [Reference Citation Analysis]
90 Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol 2013;15:370-81. [PMID: 23328811 DOI: 10.1093/neuonc/nos308] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 8.4] [Reference Citation Analysis]
91 Bujko M, Kowalewska M, Danska-Bidzinska A, Bakula-Zalewska E, Siedecki JA, Bidzinski M. The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma. Oncol Lett 2012;4:551-5. [PMID: 22970054 DOI: 10.3892/ol.2012.771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
92 Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 2012;124:547-60. [PMID: 22810491 DOI: 10.1007/s00401-012-1016-2] [Cited by in Crossref: 189] [Cited by in F6Publishing: 186] [Article Influence: 18.9] [Reference Citation Analysis]
93 Samii A, Sorokin M, Kar S, Makovskaia L, Garazha A, Hartmann C, Moisseev A, Kim E, Giese A, Buzdin A. Case of multifocal glioblastoma with four fusion transcripts of ALK, FGFR2, NTRK2, and NTRK3 genes stresses the need for tumor tissue multisampling for transcriptomic analysis. Cold Spring Harb Mol Case Stud 2021;7:a006100. [PMID: 34341009 DOI: 10.1101/mcs.a006100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Tian L, Zhou H, Wang G, Wang WY, Li Y, Xue X. The relationship between PLOD1 expression level and glioma prognosis investigated using public databases. PeerJ 2021;9:e11422. [PMID: 34040895 DOI: 10.7717/peerj.11422] [Reference Citation Analysis]
95 Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 2020;20:12-25. [PMID: 31806885 DOI: 10.1038/s41568-019-0224-7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 30.0] [Reference Citation Analysis]
96 Zhang H, Wang R, Yu Y, Liu J, Luo T, Fan F. Glioblastoma Treatment Modalities besides Surgery. J Cancer 2019;10:4793-806. [PMID: 31598150 DOI: 10.7150/jca.32475] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
97 Andronesi OC, Loebel F, Bogner W, Marjańska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res 2016;22:1632-41. [PMID: 26534967 DOI: 10.1158/1078-0432.CCR-15-0656] [Cited by in Crossref: 99] [Cited by in F6Publishing: 59] [Article Influence: 14.1] [Reference Citation Analysis]
98 Holliday EB, Sulman EP. Tumor prognostic factors and the challenge of developing predictive factors. Curr Oncol Rep 2013;15:33-46. [PMID: 23224629 DOI: 10.1007/s11912-012-0283-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Rapp M, Grauer OM, Kamp M, Sevens N, Zotz N, Sabel M, Sorg RV. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials 2018;19:293. [PMID: 29801515 DOI: 10.1186/s13063-018-2659-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
100 Lagunas-Rangel FA, Bermúdez-Cruz RM. Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells. Front Oncol 2020;10:598174. [PMID: 33330091 DOI: 10.3389/fonc.2020.598174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
101 Iafrate AJ, Louis DN. "MGMT for pt mgmt": is methylguanine-DNA methyltransferase testing ready for patient management? J Mol Diagn 2008;10:308-10. [PMID: 18556768 DOI: 10.2353/jmoldx.2008.080043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
102 Xu X, Stockhammer F, Schmitt M. Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin Dev Immunol 2012;2012:764213. [PMID: 22474481 DOI: 10.1155/2012/764213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
103 Lee YW, Cho HJ, Lee WH, Sonntag WE. Whole brain radiation-induced cognitive impairment: pathophysiological mechanisms and therapeutic targets. Biomol Ther (Seoul) 2012;20:357-70. [PMID: 24009822 DOI: 10.4062/biomolther.2012.20.4.357] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
104 Carr MT, Hochheimer CJ, Rock AK, Dincer A, Ravindra L, Zhang FL, Opalak CF, Poulos N, Sima AP, Broaddus WC. Comorbid Medical Conditions as Predictors of Overall Survival in Glioblastoma Patients. Sci Rep 2019;9:20018. [PMID: 31882968 DOI: 10.1038/s41598-019-56574-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Hervey-Jumper SL, Berger MS. Role of surgical resection in low- and high-grade gliomas. Curr Treat Options Neurol 2014;16:284. [PMID: 24595756 DOI: 10.1007/s11940-014-0284-7] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 11.8] [Reference Citation Analysis]
106 Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9:444. [PMID: 20015387 DOI: 10.1186/1471-2407-9-444] [Cited by in Crossref: 122] [Cited by in F6Publishing: 126] [Article Influence: 9.4] [Reference Citation Analysis]
107 Hamilton MG, Roldán G, Magliocco A, McIntyre JB, Parney I, Easaw JC. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J Neurooncol 2011;102:255-60. [PMID: 20652362 DOI: 10.1007/s11060-010-0307-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
108 Pridham KJ, Shah F, Hutchings KR, Sheng KL, Guo S, Liu M, Kanabur P, Lamouille S, Lewis G, Morales M, Jourdan J, Grek CL, Ghatnekar GG, Varghese R, Kelly DF, Gourdie RG, Sheng Z. Connexin 43 confers chemoresistance through activating PI3K. Oncogenesis 2022;11:2. [PMID: 35022385 DOI: 10.1038/s41389-022-00378-7] [Reference Citation Analysis]
109 Abrey LE. Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme. Curr Neurol Neurosci Rep 2005;5:167-8. [PMID: 15865881 DOI: 10.1007/s11910-005-0043-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int 2010;107:799-807; quiz 808. [PMID: 21124703 DOI: 10.3238/arztebl.2010.0799] [Cited by in Crossref: 6] [Cited by in F6Publishing: 21] [Article Influence: 0.5] [Reference Citation Analysis]
111 Liu B, Liu J, Liao Y, Jin C, Zhang Z, Zhao J, Liu K, Huang H, Cao H, Cheng Q. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma. Med Sci Monit 2019;25:3624-35. [PMID: 31094363 DOI: 10.12659/MSM.916648] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
112 Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, Reardon DA. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep 2011;13:42-9. [PMID: 21125354 DOI: 10.1007/s11912-010-0144-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
113 Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 2016;18:1357-66. [PMID: 27370400 DOI: 10.1093/neuonc/now132] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 13.8] [Reference Citation Analysis]
114 Shoji T, Saito R, Chonan M, Shibahara I, Sato A, Kanamori M, Sonoda Y, Kondo T, Ishii N, Tominaga T. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. Neuro Oncol 2016;18:1120-8. [PMID: 26917236 DOI: 10.1093/neuonc/now023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
115 Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 2016;4:79. [PMID: 27503138 DOI: 10.1186/s40478-016-0351-2] [Cited by in Crossref: 112] [Cited by in F6Publishing: 111] [Article Influence: 18.7] [Reference Citation Analysis]
116 Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol 2012;107:617-31. [PMID: 22287028 DOI: 10.1007/s11060-011-0787-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
117 Sorribes IC, Handelman SK, Jain HV. Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition. J R Soc Interface 2020;17:20190722. [PMID: 31964274 DOI: 10.1098/rsif.2019.0722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
118 Everhard S, Tost J, El Abdalaoui H, Crinière E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 2009;11:348-356. [PMID: 19224763 DOI: 10.1215/15228517-2009-001] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 8.3] [Reference Citation Analysis]
119 Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, Bernstock JD, Choi BD, Sampson JH. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Rev Clin Pharmacol 2020;13:1147-58. [PMID: 32862726 DOI: 10.1080/17512433.2020.1817737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Li QJ, Cai JQ, Liu CY. Evolving Molecular Genetics of Glioblastoma. Chin Med J (Engl) 2016;129:464-71. [PMID: 26879021 DOI: 10.4103/0366-6999.176065] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
121 Elson A, Bovi J, Siker M, Schultz C, Paulson E. Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma. J Neurooncol 2015;122:549-58. [PMID: 25700835 DOI: 10.1007/s11060-015-1743-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
122 Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol 2016;126:309-16. [PMID: 26508094 DOI: 10.1007/s11060-015-1966-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
123 Salvati M, Formichella AI, D'Elia A, Brogna C, Frati A, Giangaspero F, Delfini R, Santoro A. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 2009;94:129-34. [PMID: 19343483 DOI: 10.1007/s11060-009-9815-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
124 Kriel J, Müller-Nedebock K, Maarman G, Mbizana S, Ojuka E, Klumperman B, Loos B. Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics. Sci Rep 2018;8:10348. [PMID: 29985441 DOI: 10.1038/s41598-018-28590-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
125 Levy JJ, Chen Y, Azizgolshani N, Petersen CL, Titus AJ, Moen EL, Vaickus LJ, Salas LA, Christensen BC. MethylSPWNet and MethylCapsNet: Biologically Motivated Organization of DNAm Neural Networks, Inspired by Capsule Networks. NPJ Syst Biol Appl 2021;7:33. [PMID: 34417465 DOI: 10.1038/s41540-021-00193-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Nalejska E, Mączyńska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther 2014;18:273-84. [PMID: 24385403 DOI: 10.1007/s40291-013-0077-9] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 11.4] [Reference Citation Analysis]
127 Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 2011;13:84-98. [PMID: 20926426 DOI: 10.1093/neuonc/noq110] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 7.4] [Reference Citation Analysis]
128 Klement RJ, Popp I, Kaul D, Ehret F, Grosu AL, Polat B, Sweeney RA, Lewitzki V. Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis. J Neurooncol 2021. [PMID: 34940951 DOI: 10.1007/s11060-021-03926-0] [Reference Citation Analysis]
129 Qureshi IA, Mehler MF. Developing epigenetic diagnostics and therapeutics for brain disorders. Trends Mol Med 2013;19:732-41. [PMID: 24145019 DOI: 10.1016/j.molmed.2013.09.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
130 Majchrzak-Celińska A, Dybska E, Barciszewska AM. DNA methylation analysis with methylation-sensitive high-resolution melting (MS-HRM) reveals gene panel for glioma characteristics. CNS Neurosci Ther 2020;26:1303-14. [PMID: 32783304 DOI: 10.1111/cns.13443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
131 Yang YN, Zhang XH, Wang YM, Zhang X, Gu Z. miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-α in glioblastoma. Oncol Lett 2018;15:7563-70. [PMID: 29725461 DOI: 10.3892/ol.2018.8301] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
132 Choudhury SR, Cui Y, Milton JR, Li J, Irudayaraj J. Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma. Clin Epigenetics 2015;7:107. [PMID: 26451167 DOI: 10.1186/s13148-015-0140-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
133 Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 2011;6:e17156. [PMID: 21365007 DOI: 10.1371/journal.pone.0017156] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
134 Pretanvil JA, Salinas IQ, Piccioni DE. Glioblastoma in the elderly: treatment patterns and survival. CNS Oncol 2017;6:19-28. [PMID: 28001088 DOI: 10.2217/cns-2016-0023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
135 Liu HW, Lee PM, Bamodu OA, Su YK, Fong IH, Yeh CT, Chien MH, Kan IH, Lin CM. Enhanced Hsa-miR-181d/p-STAT3 and Hsa-miR-181d/p-STAT5A Ratios Mediate the Anticancer Effect of Garcinol in STAT3/5A-Addicted Glioblastoma. Cancers (Basel) 2019;11:E1888. [PMID: 31783691 DOI: 10.3390/cancers11121888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
136 Teuber-Hanselmann S, Worm K, Macha N, Junker A. MGMT-Methylation in Non-Neoplastic Diseases of the Central Nervous System. Int J Mol Sci 2021;22:3845. [PMID: 33917711 DOI: 10.3390/ijms22083845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Christoph S, Alexander Q, Fritz T, Walter SS, Steffi U, Ralf K, Joachim O. MiRNA-181d expression correlates in tumor versus plasma of glioblastoma patients - the base of a preoperative stratification tool for local carmustine wafer use. World Neurosurg 2021:S1878-8750(21)01897-0. [PMID: 34942386 DOI: 10.1016/j.wneu.2021.12.053] [Reference Citation Analysis]
138 Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, Soroceanu L. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis 2015;6:e1601. [PMID: 25590811 DOI: 10.1038/cddis.2014.566] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 15.4] [Reference Citation Analysis]
139 Kusabe Y, Kawashima H, Ogose A, Sasaki T, Ariizumi T, Hotta T, Endo N. Effect of temozolomide on the viability of musculoskeletal sarcoma cells. Oncol Lett 2015;10:2511-8. [PMID: 26622881 DOI: 10.3892/ol.2015.3506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
140 Álvarez-Torres MDM, Fuster-García E, Balaña C, Puig J, García-Gómez JM. Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT. Cancers (Basel) 2021;13:5420. [PMID: 34771583 DOI: 10.3390/cancers13215420] [Reference Citation Analysis]
141 Tea MN, Poonnoose SI, Pitson SM. Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. Cancers (Basel) 2020;12:E111. [PMID: 31906280 DOI: 10.3390/cancers12010111] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
142 Taslimi S, Ye VC, Zadeh G. Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease. Neurooncol Adv 2021;3:vdab028. [PMID: 34042102 DOI: 10.1093/noajnl/vdab028] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Blakeley JO, Grossman SA, Mikkelsen T, Rosenfeld MR, Peereboom D, Nabors LB, Chi AS, Emmons G, Garcia Ribas I, Supko JG, Desideri S, Ye X. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. J Neurooncol 2015;125:123-31. [PMID: 26285766 DOI: 10.1007/s11060-015-1876-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
144 Roh TH, Park HH, Kang SG, Moon JH, Kim EH, Hong CK, Ahn SS, Choi HJ, Cho J, Kim SH, Lee SK, Kim DS, Kim SH, Suh CO, Lee KS, Chang JH. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. Medicine (Baltimore) 2017;96:e7422. [PMID: 28682902 DOI: 10.1097/MD.0000000000007422] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
145 Jakob J, Hille M, Sauer C, Ströbel P, Wenz F, Hohenberger P. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma. Radiat Oncol 2012;7:180. [PMID: 23110891 DOI: 10.1186/1748-717X-7-180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
146 Dejaegher J, Solie L, Hunin Z, Sciot R, Capper D, Siewert C, Van Cauter S, Wilms G, van Loon J, Ectors N, Fieuws S, Pfister SM, Van Gool SW, De Vleeschouwer S. DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro Oncol 2021;23:240-50. [PMID: 33130898 DOI: 10.1093/neuonc/noaa247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
147 Piccirillo SG, Binda E, Fiocco R, Vescovi AL, Shah K. Brain cancer stem cells. J Mol Med (Berl) 2009;87:1087-95. [PMID: 19784875 DOI: 10.1007/s00109-009-0535-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
148 He X, Zhang S, Chen J, Li D. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma. Cancer Med 2019;8:2031-40. [PMID: 30848102 DOI: 10.1002/cam4.2075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Trejo-Solís C, Serrano-Garcia N, Escamilla-Ramírez Á, Castillo-Rodríguez RA, Jimenez-Farfan D, Palencia G, Calvillo M, Alvarez-Lemus MA, Flores-Nájera A, Cruz-Salgado A, Sotelo J. Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma. Int J Mol Sci 2018;19:E3773. [PMID: 30486451 DOI: 10.3390/ijms19123773] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
150 Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther 2017;8:99-113. [PMID: 28989289 DOI: 10.2147/AHMT.S53391] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 6.6] [Reference Citation Analysis]
151 Xi X, Chu Y, Liu N, Wang Q, Yin Z, Lu Y, Chen Y. Joint bioinformatics analysis of underlying potential functions of hsa-let-7b-5p and core genes in human glioma. J Transl Med 2019;17:129. [PMID: 30995921 DOI: 10.1186/s12967-019-1882-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
152 Martínez R, Stühmer W, Martin S, Schell J, Reichmann A, Rohde V, Pardo L. Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival. BMC Cancer 2015;15:839. [PMID: 26530050 DOI: 10.1186/s12885-015-1848-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
153 Wang W, Zhang L, Wang Z, Yang F, Wang H, Liang T, Wu F, Lan Q, Wang J, Zhao J. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Oncotarget 2016;7:69991-9. [PMID: 27588397 DOI: 10.18632/oncotarget.11726] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
154 Stetson LC, Dazard JE, Barnholtz-Sloan JS. Protein Markers Predict Survival in Glioma Patients. Mol Cell Proteomics 2016;15:2356-65. [PMID: 27143410 DOI: 10.1074/mcp.M116.060657] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
155 Yamada K, Tso J, Ye F, Choe J, Liu Y, Liau LM, Tso CL. Essential gene pathways for glioblastoma stem cells: clinical implications for prevention of tumor recurrence. Cancers (Basel) 2011;3:1975-95. [PMID: 24212792 DOI: 10.3390/cancers3021975] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
156 Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, Wesseling P, Hulsebos TJ, Troost D, van Tilborg AA, Leenstra S, Vandertop WP, Bardelli A, van Noorden CJ, Bleeker FE. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014;16:1263-73. [PMID: 24510240 DOI: 10.1093/neuonc/nou005] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 12.8] [Reference Citation Analysis]
157 Marinari E, Allard M, Gustave R, Widmer V, Philippin G, Merkler D, Tsantoulis P, Dutoit V, Dietrich PY. Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. Oncoimmunology 2020;9:1779990. [PMID: 32923142 DOI: 10.1080/2162402X.2020.1779990] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
158 De Meyer T, Mampaey E, Vlemmix M, Denil S, Trooskens G, Renard JP, De Keulenaer S, Dehan P, Menschaert G, Van Criekinge W. Quality evaluation of methyl binding domain based kits for enrichment DNA-methylation sequencing. PLoS One 2013;8:e59068. [PMID: 23554971 DOI: 10.1371/journal.pone.0059068] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
159 Ramakrishna R, Pisapia D. Recent Molecular Advances in Our Understanding of Glioma. Cureus 2015;7:e287. [PMID: 26244119 DOI: 10.7759/cureus.287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
160 Lee JY, Park CK, Park SH, Wang KC, Cho BK, Kim SK. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Childs Nerv Syst 2011;27:1877-83. [PMID: 21789683 DOI: 10.1007/s00381-011-1525-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
161 Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. J Carcinog. 2013;12:20. [PMID: 24319345 DOI: 10.4103/1477-3163.120632] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
162 Spratt DE, Folkert M, Zumsteg ZS, Chan TA, Beal K, Gutin PH, Pentsova E, Yamada Y. Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. J Neurooncol 2014;116:357-63. [PMID: 24190580 DOI: 10.1007/s11060-013-1302-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
163 Chung EY, Dews M, Maity A, Thomas-Tikhonenko A. Aiding and ABT'ing Treatment for Glioblastoma. Cancer Biol Ther 2007;6:802-4. [PMID: 17568181 DOI: 10.4161/cbt.6.5.4431] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
164 Johnson DR, Wefel JS. Relationship between cognitive function and prognosis in glioblastoma. CNS Oncol 2013;2:195-201. [PMID: 25057978 DOI: 10.2217/cns.13.5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
165 Festuccia C, Mancini A, Colapietro A, Gravina GL, Vitale F, Marampon F, Delle Monache S, Pompili S, Cristiano L, Vetuschi A, Tombolini V, Chen Y, Mehrling T. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol 2018;11:32. [PMID: 29486795 DOI: 10.1186/s13045-018-0576-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
166 Pacaud R, Cheray M, Nadaradjane A, Vallette FM, Cartron PF. Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy. Theranostics. 2015;5:12-22. [PMID: 25553095 DOI: 10.7150/thno.8799] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
167 Lee E, Pain M, Wang H, Herman JA, Toledo CM, DeLuca JG, Yong RL, Paddison P, Zhu J. Sensitivity to BUB1B Inhibition Defines an Alternative Classification of Glioblastoma. Cancer Res 2017;77:5518-29. [PMID: 28855212 DOI: 10.1158/0008-5472.CAN-17-0736] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
168 Cartron PF, Blanquart C, Hervouet E, Gregoire M, Vallette FM. HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression. Mol Oncol 2013;7:452-63. [PMID: 23312906 DOI: 10.1016/j.molonc.2012.11.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
169 Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012;38:271-91. [PMID: 22098029 DOI: 10.1111/j.1365-2990.2011.01238.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
170 Pointer KB, Clark PA, Eliceiri KW, Salamat MS, Robertson GA, Kuo JS. Administration of Non-Torsadogenic human Ether-à-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG-Expressing Glioblastoma Patients. Clin Cancer Res 2017;23:73-80. [PMID: 27635088 DOI: 10.1158/1078-0432.CCR-15-3169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
171 Huang AZ, Delaidelli A, Sorensen PH. RNA modifications in brain tumorigenesis. Acta Neuropathol Commun 2020;8:64. [PMID: 32375856 DOI: 10.1186/s40478-020-00941-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
172 Afghani N, Mehta T, Wang J, Tang N, Skalli O, Quick QA. Microtubule actin cross-linking factor 1, a novel target in glioblastoma. Int J Oncol 2017;50:310-6. [PMID: 27959385 DOI: 10.3892/ijo.2016.3798] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
173 Chen X, Zeng M, Tong Y, Zhang T, Fu Y, Li H, Zhang Z, Cheng Z, Xu X, Yang R, Liu Z, Wei X, Jiang X. Automatic Prediction of MGMT Status in Glioblastoma via Deep Learning-Based MR Image Analysis. Biomed Res Int 2020;2020:9258649. [PMID: 33029531 DOI: 10.1155/2020/9258649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
174 Salinas RD, Durgin JS, O'Rourke DM. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. CNS Drugs 2020;34:127-45. [PMID: 31916100 DOI: 10.1007/s40263-019-00687-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
175 Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13:2038-45. [PMID: 17404084 DOI: 10.1158/1078-0432.CCR-06-2149] [Cited by in Crossref: 279] [Cited by in F6Publishing: 153] [Article Influence: 18.6] [Reference Citation Analysis]
176 Brandes AA, Tosoni A, Franceschi E. Adjuvant therapy in glioblastomas: false steps and real advances. Expert Review of Anticancer Therapy 2014;7:607-8. [DOI: 10.1586/14737140.7.5.607] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
177 Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L. O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Int J Mol Sci 2012;13:6983-94. [PMID: 22837675 DOI: 10.3390/ijms13066983] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
178 Kurscheid S, Bady P, Sciuscio D, Samarzija I, Shay T, Vassallo I, Criekinge WV, Daniel RT, van den Bent MJ, Marosi C, Weller M, Mason WP, Domany E, Stupp R, Delorenzi M, Hegi ME. Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biol 2015;16:16. [PMID: 25622821 DOI: 10.1186/s13059-015-0583-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 7.7] [Reference Citation Analysis]
179 Rimel BJ, Huettner P, Powell MA, Mutch DG, Goodfellow PJ. Absence of MGMT promoter methylation in endometrial cancer. Gynecol Oncol 2009;112:224-8. [PMID: 18973931 DOI: 10.1016/j.ygyno.2008.08.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
180 Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453. [PMID: 17456751 DOI: 10.2353/ajpath.2007.070011] [Cited by in Crossref: 895] [Cited by in F6Publishing: 790] [Article Influence: 59.7] [Reference Citation Analysis]
181 Neville IS, Dos Santos AG, Almeida CC, Abaurre LB, Wayhs SY, Feher O, Teixeira MJ, Lepski G. Reoperation for recurrent glioblastomas: What to expect? Surg Neurol Int 2021;12:42. [PMID: 33598358 DOI: 10.25259/SNI_538_2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Lin AL, Liu J, Evans J, Leuthardt EC, Rich KM, Dacey RG, Dowling JL, Kim AH, Zipfel GJ, Grubb RL, Huang J, Robinson CG, Simpson JR, Linette GP, Chicoine MR, Tran DD. Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. Neuro Oncol 2014;16:123-30. [PMID: 24285548 DOI: 10.1093/neuonc/not142] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
183 Vivekanandarajah A, Krishnarasa B, Mourad M, Aoun N, Odaimi M. Achievement of three year remission with bevacizumab and irinotecan in recurrent glioblastoma multiforme: a case report. Clin Med Insights Oncol 2011;5:15-21. [PMID: 21499558 DOI: 10.4137/CMO.S6525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
184 Storvall S, Ryhänen E, Bensch FV, Heiskanen I, Kytölä S, Ebeling T, Mäkelä S, Schalin-Jäntti C. Recurrent Metastasized Parathyroid Carcinoma-Long-Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide. JBMR Plus 2019;3:e10114. [PMID: 31044184 DOI: 10.1002/jbm4.10114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
185 Braun K, Ahluwalia MS. Treatment of Glioblastoma in Older Adults. Curr Oncol Rep 2017;19:81. [PMID: 29075865 DOI: 10.1007/s11912-017-0644-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
186 Cho HR, Kumari N, Thakur N, Vu HT, Kim H, Choi SH. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging. Sci Rep 2019;9:16613. [PMID: 31719653 DOI: 10.1038/s41598-019-53147-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
187 Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, Schulz M, Hutter G, Hench J, Schucht P, Boulay JL, Mariani L. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol 2013;15:469-79. [PMID: 23408861 DOI: 10.1093/neuonc/nos317] [Cited by in Crossref: 117] [Cited by in F6Publishing: 106] [Article Influence: 13.0] [Reference Citation Analysis]
188 Mozhei O, G Teschemacher A, Kasparov S. Viral Vectors as Gene Therapy Agents for Treatment of Glioblastoma. Cancers (Basel) 2020;12:E3724. [PMID: 33322507 DOI: 10.3390/cancers12123724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Susman S, Pîrlog R, Leucuța D, Mitre AO, Padurean VA, Melincovici C, Moldovan I, Crișan D, Florian SI. The role of p-Stat3 Y705 immunohistochemistry in glioblastoma prognosis. Diagn Pathol 2019;14:124. [PMID: 31690341 DOI: 10.1186/s13000-019-0903-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
190 Fueyo J, Gomez-Manzano C, Yung WK. Advances in translational research in neuro-oncology. Arch Neurol 2011;68:303-8. [PMID: 21059986 DOI: 10.1001/archneurol.2010.293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
191 Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 2010;70:453-62. [PMID: 20068170 DOI: 10.1158/0008-5472.CAN-09-2189] [Cited by in Crossref: 93] [Cited by in F6Publishing: 70] [Article Influence: 7.8] [Reference Citation Analysis]
192 Regnery S, Adeberg S, Dreher C, Oberhollenzer J, Meissner JE, Goerke S, Windschuh J, Deike-Hofmann K, Bickelhaupt S, Zaiss M, Radbruch A, Bendszus M, Wick W, Unterberg A, Rieken S, Debus J, Bachert P, Ladd M, Schlemmer HP, Paech D. Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. Oncotarget 2018;9:28772-83. [PMID: 29983895 DOI: 10.18632/oncotarget.25594] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
193 Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent MJ; Dutch Society for Neuro-Oncology. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol 2011;13:235-41. [PMID: 21177338 DOI: 10.1093/neuonc/noq177] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
194 Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist 2021;4:17-43. [PMID: 34337348 DOI: 10.20517/cdr.2020.79] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Dong CY, Cui J, Li DH, Li Q, Hong XY. HOXA10‑AS: A novel oncogenic long non‑coding RNA in glioma. Oncol Rep 2018;40:2573-83. [PMID: 30132568 DOI: 10.3892/or.2018.6662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
196 Nagel ZD, Chaim IA, Samson LD. Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research. DNA Repair (Amst) 2014;19:199-213. [PMID: 24780560 DOI: 10.1016/j.dnarep.2014.03.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
197 Barker CA, Chang M, Chou JF, Zhang Z, Beal K, Gutin PH, Iwamoto FM. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol. 2012;109:391-397. [PMID: 22688802 DOI: 10.1007/s11060-012-0906-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
198 Kim IK, Kim K, Lee E, Oh DS, Park CS, Park S, Yang JM, Kim JH, Kim HS, Shima DT, Kim JH, Hong SH, Cho YH, Kim YH, Park JB, Koh GY, Ju YS, Lee HK, Lee S, Kim I. Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. J Exp Med 2018;215:963-83. [PMID: 29444818 DOI: 10.1084/jem.20170123] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
199 Evans WE, Pui CH, Yang JJ. The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead. Clin Pharmacol Ther 2020;107:176-80. [PMID: 31563145 DOI: 10.1002/cpt.1660] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
200 Chai Y, Wang C, Liu W, Fan Y, Zhang Y. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma. J Neurooncol 2019;144:293-301. [PMID: 31236818 DOI: 10.1007/s11060-019-03226-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
201 Fuster-Garcia E, Lorente Estellés D, Álvarez-Torres MDM, Juan-Albarracín J, Chelebian E, Rovira A, Acosta CA, Pineda J, Oleaga L, Mollá-Olmos E, Filice S, Due-Tønnessen P, Meling TR, Emblem KE, García-Gómez JM. MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas. Eur Radiol 2021;31:1738-47. [PMID: 33001310 DOI: 10.1007/s00330-020-07297-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
202 Blumcke I, Aronica E, Urbach H, Alexopoulos A, Gonzalez-Martinez JA. A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. Acta Neuropathol. 2014;128:39-54. [PMID: 24858213 DOI: 10.1007/s00401-014-1288-9] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 11.1] [Reference Citation Analysis]
203 Balvers RK, Lamfers ML, Kloezeman JJ, Kleijn A, Berghauser Pont LM, Dirven CM, Leenstra S. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. J Transl Med 2015;13:74. [PMID: 25886061 DOI: 10.1186/s12967-015-0427-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
204 Wood MD, Halfpenny AM, Moore SR. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagn Pathol 2019;14:29. [PMID: 30967140 DOI: 10.1186/s13000-019-0802-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
205 Kong Z, Lin Y, Jiang C, Li L, Liu Z, Wang Y, Dai C, Liu D, Qin X, Wang Y, Liu Z, Cheng X, Tian J, Ma W. 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma. Cancer Imaging 2019;19:58. [PMID: 31426864 DOI: 10.1186/s40644-019-0246-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
206 Bezecny P. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Med Oncol 2014;31:985. [PMID: 24838514 DOI: 10.1007/s12032-014-0985-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
207 Burton E, Yusuf M, Gilbert MR, Gaskins J, Woo S. Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients. J Geriatr Oncol 2020;11:680-7. [PMID: 31521589 DOI: 10.1016/j.jgo.2019.08.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
208 Saraf R, Agah S, Datta A, Jiang X. Drug target ranking for glioblastoma multiforme. BMC Biomed Eng 2021;3:7. [PMID: 33902757 DOI: 10.1186/s42490-021-00052-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O. Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia 2018;20:710-20. [PMID: 29852323 DOI: 10.1016/j.neo.2018.05.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
210 Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging 2018;2018:6828396. [PMID: 30627060 DOI: 10.1155/2018/6828396] [Cited by in Crossref: 58] [Cited by in F6Publishing: 40] [Article Influence: 14.5] [Reference Citation Analysis]
211 Lønning PE, Eikesdal HP, Løes IM, Knappskog S. Constitutional Mosaic Epimutations - a hidden cause of cancer? Cell Stress 2019;3:118-35. [PMID: 31225507 DOI: 10.15698/cst2019.04.183] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
212 Chamdine O, Gajjar A. Molecular characteristics of pediatric high-grade gliomas. CNS Oncol 2014;3:433-43. [PMID: 25438814 DOI: 10.2217/cns.14.43] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
213 Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31:4085-4091. [PMID: 24101040 DOI: 10.1200/jco.2013.49.6067] [Cited by in Crossref: 89] [Cited by in F6Publishing: 55] [Article Influence: 9.9] [Reference Citation Analysis]
214 Nencha U, Rahimian A, Giry M, Sechi A, Mokhtari K, Polivka M, Schmitt Y, Di Stefano AL, Alentorn A, Labussière M, Sanson M. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. J Neurooncol 2016;126:441-6. [PMID: 26608520 DOI: 10.1007/s11060-015-1999-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
215 Hirohata T, Ishii Y, Matsuno A. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. Neurol Med Chir (Tokyo) 2014;54:966-73. [PMID: 25446382 DOI: 10.2176/nmc.ra.2014-0178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
216 Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, Fiveash JB, Gillespie GY. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 2014;22:1048-55. [PMID: 24572293 DOI: 10.1038/mt.2014.22] [Cited by in Crossref: 126] [Cited by in F6Publishing: 122] [Article Influence: 15.8] [Reference Citation Analysis]
217 Pietanza MC, Rudin CM. Novel therapeutic approaches for small cell lung cancer: the future has arrived. Curr Probl Cancer 2012;36:156-73. [PMID: 22495056 DOI: 10.1016/j.currproblcancer.2012.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
218 Walid MS. Prognostic factors for long-term survival after glioblastoma. Perm J 2008;12:45-8. [PMID: 21339920 DOI: 10.7812/tpp/08-027] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
219 Silva-Hirschberg C, Hartman H, Stack S, Swenson S, Minea RO, Davitz MA, Chen TC, Schönthal AH. Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro. Ther Adv Med Oncol 2019;11:1758835919891567. [PMID: 31839810 DOI: 10.1177/1758835919891567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
220 Williams MJ, Singleton WG, Lowis SP, Malik K, Kurian KM. Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma. Front Oncol 2017;7:45. [PMID: 28401060 DOI: 10.3389/fonc.2017.00045] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
221 Cioffi G, Cote DJ, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. Neurooncol Pract 2020;7:299-305. [PMID: 32537179 DOI: 10.1093/nop/npaa001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Sun Q, Chen Y, Liang C, Zhao Y, Lv X, Zou Y, Yan K, Zheng H, Liang D, Li ZC. Biologic Pathways Underlying Prognostic Radiomics Phenotypes from Paired MRI and RNA Sequencing in Glioblastoma. Radiology 2021;301:654-63. [PMID: 34519578 DOI: 10.1148/radiol.2021203281] [Reference Citation Analysis]
223 Kim HJ, Kim DY. Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. Molecules 2020;25:E4641. [PMID: 33053763 DOI: 10.3390/molecules25204641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Putz F, Putz T, Goerig N, Knippen S, Gryc T, Eyüpoglu I, Rössler K, Semrau S, Lettmaier S, Fietkau R. Improved survival for elderly married glioblastoma patients : Better treatment delivery, less toxicity, and fewer disease complications. Strahlenther Onkol 2016;192:797-805. [PMID: 27628965 DOI: 10.1007/s00066-016-1046-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
225 Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther 2015;14:2735-43. [PMID: 26438157 DOI: 10.1158/1535-7163.MCT-15-0553] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 7.1] [Reference Citation Analysis]
226 Groenendijk FH, Taal W, Dubbink HJ, Haarloo CR, Kouwenhoven MC, van den Bent MJ, Kros JM, Dinjens WN. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol 2011;101:405-17. [PMID: 20593220 DOI: 10.1007/s11060-010-0274-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
227 Chonan M, Saito R, Shoji T, Shibahara I, Kanamori M, Sonoda Y, Watanabe M, Kikuchi T, Ishii N, Tominaga T. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models. Neuro Oncol 2015;17:1453-62. [PMID: 26008605 DOI: 10.1093/neuonc/nov090] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
228 Areeb Z, Stuart SF, West AJ, Gomez J, Nguyen HPT, Paradiso L, Zulkifli A, Jones J, Kaye AH, Morokoff AP, Luwor RB. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. Sci Rep 2020;10:17768. [PMID: 33082482 DOI: 10.1038/s41598-020-74746-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
229 Mansour NM, Bernal GM, Wu L, Crawley CD, Cahill KE, Voce DJ, Balyasnikova IV, Zhang W, Spretz R, Nunez L, Larsen GF, Weichselbaum RR, Yamini B. Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide. Cancer Res 2015;75:2039-48. [PMID: 25808868 DOI: 10.1158/0008-5472.CAN-14-2144] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
230 Lan T, Zhao Z, Qu Y, Zhang M, Wang H, Zhang Z, Zhou W, Fan X, Yu C, Zhan Q, Song Y. Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling. Oncotarget 2016;7:55555-71. [PMID: 27487130 DOI: 10.18632/oncotarget.10864] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
231 Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain Sci 2018;8:E15. [PMID: 29337870 DOI: 10.3390/brainsci8010015] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 14.3] [Reference Citation Analysis]
232 Kong L, Gao J, Hu J, Lu R, Yang J, Qiu X, Hu W, Lu JJ. Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial. Cancer Commun (Lond) 2019;39:5. [PMID: 30786916 DOI: 10.1186/s40880-019-0351-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
233 Rocha CR, Kajitani GS, Quinet A, Fortunato RS, Menck CF. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget. 2016;7:48081-48092. [PMID: 27344172 DOI: 10.18632/oncotarget.10129] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
234 Hong JM, Kim JH, Kim H, Lee WJ, Hwang YI. SB365, Pulsatilla Saponin D Induces Caspase-Independent Cell Death and Augments the Anticancer Effect of Temozolomide in Glioblastoma Multiforme Cells. Molecules 2019;24:E3230. [PMID: 31491945 DOI: 10.3390/molecules24183230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
235 Jin J, Choi SH, Lee JE, Joo JD, Han JH, Park SY, Kim CY. Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. Oncol Lett 2017;13:3767-73. [PMID: 28529591 DOI: 10.3892/ol.2017.5918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
236 Oronsky B, Reid TR, Oronsky A, Sandhu N, Knox SJ. A Review of Newly Diagnosed Glioblastoma. Front Oncol 2020;10:574012. [PMID: 33614476 DOI: 10.3389/fonc.2020.574012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
237 Sanvito F, Castellano A, Falini A. Advancements in Neuroimaging to Unravel Biological and Molecular Features of Brain Tumors. Cancers (Basel) 2021;13:424. [PMID: 33498680 DOI: 10.3390/cancers13030424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
238 Pfaff E, Kessler T, Balasubramanian GP, Berberich A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Dettmer S, Brors B, Platten M, Pfister SM, von Deimling A, Jones DTW, Wick W, Sahm F. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study. Neuro Oncol 2018;20:826-37. [PMID: 29165638 DOI: 10.1093/neuonc/nox216] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
239 Luan XZ, Wang HR, Xiang W, Li SJ, He H, Chen LG, Wang JM, Zhou J. Extracranial multiorgan metastasis from primary glioblastoma: A case report. World J Clin Cases 2021; 9(33): 10300-10307 [PMID: 34904103 DOI: 10.12998/wjcc.v9.i33.10300] [Reference Citation Analysis]
240 Balañá C, Vaz MA, Lopez D, de la Peñas R, García-Bueno JM, Molina-Garrido MJ, Sepúlveda JM, Cano JM, Bugés C, Sanz SM, Arranz JL, Perez-Segura P, Rodriguez A, Martin JM, Benavides M, Gil M. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. Clin Transl Oncol 2014;16:273-9. [PMID: 23793813 DOI: 10.1007/s12094-013-1068-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
241 Sun S, Lee D, Ho AS, Pu JK, Zhang XQ, Lee NP, Day PJ, Lui WM, Fung CF, Leung GK. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol 2013;15:562-77. [PMID: 23444257 DOI: 10.1093/neuonc/not005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
242 Garrett AM, Lastakchi S, McConville C. The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study. Genes (Basel) 2020;11:E173. [PMID: 32041307 DOI: 10.3390/genes11020173] [Reference Citation Analysis]
243 Jiang H, Zeng W, Ren X, Cui Y, Li M, Yang K, Elbaroody M, Lin S. Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study. J Neurooncol 2019;144:127-35. [PMID: 31175579 DOI: 10.1007/s11060-019-03211-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
244 Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K. Emerging targets for glioblastoma stem cell therapy. J Biomed Res 2016;30:19-31. [PMID: 26616589 DOI: 10.7555/JBR.30.20150100] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
245 Umans RA, Sontheimer H. Combating malignant astrocytes: Strategies mitigating tumor invasion. Neurosci Res 2018;126:22-30. [PMID: 29054465 DOI: 10.1016/j.neures.2017.09.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
246 Bostian AC, Eoff RL. Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas. Chem Res Toxicol 2016;29:1369-80. [PMID: 27482758 DOI: 10.1021/acs.chemrestox.6b00255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
247 Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-94. [PMID: 20713493 DOI: 10.1158/1078-0432.CCR-09-1811] [Cited by in Crossref: 92] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
248 Repka MC, Lei S, Campbell L, Suy S, Voyadzis JM, Kalhorn C, McGrail K, Jean W, Subramaniam DS, Lischalk JW, Collins SP, Collins BT. Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk. Front Oncol 2018;8:373. [PMID: 30254985 DOI: 10.3389/fonc.2018.00373] [Reference Citation Analysis]
249 Khalifa J, Tensaouti F, Lusque A, Plas B, Lotterie JA, Benouaich-Amiel A, Uro-Coste E, Lubrano V, Cohen-Jonathan Moyal E. Subventricular zones: new key targets for glioblastoma treatment. Radiat Oncol 2017;12:67. [PMID: 28424082 DOI: 10.1186/s13014-017-0791-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
250 Perry C, Agarwal D, Abdel-Fatah TM, Lourdusamy A, Grundy R, Auer DT, Walker D, Lakhani R, Scott IS, Chan S, Ball G, Madhusudan S. Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. Oncotarget 2014;5:5764-81. [PMID: 25026297 DOI: 10.18632/oncotarget.2180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
251 Khan AA, Ibad H, Ahmed KS, Hoodbhoy Z, Shamim SM. Deep learning applications in neuro-oncology. Surg Neurol Int 2021;12:435. [PMID: 34513198 DOI: 10.25259/SNI_433_2021] [Reference Citation Analysis]
252 Guillaumet-Adkins A, Richter J, Odero MD, Sandoval J, Agirre X, Catala A, Esteller M, Prósper F, Calasanz MJ, Buño I, Kwon M, Court F, Siebert R, Monk D. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. J Hematol Oncol 2014;7:4. [PMID: 24405639 DOI: 10.1186/1756-8722-7-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
253 Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar BA, Ménard C, Kiehl TR, Perkins BA, Chung C. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neurooncol 2015;124:119-26. [PMID: 26015297 DOI: 10.1007/s11060-015-1815-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
254 Rundle-Thiele D, Head R, Cosgrove L, Martin JH. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma. Br J Clin Pharmacol 2016;81:199-209. [PMID: 26374633 DOI: 10.1111/bcp.12785] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
255 Li Y, Lupo JM, Polley MY, Crane JC, Bian W, Cha S, Chang S, Nelson SJ. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro Oncol 2011;13:546-57. [PMID: 21297128 DOI: 10.1093/neuonc/noq194] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
256 Annovazzi L, Mellai M, Schiffer D. Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma. Cancers (Basel) 2017;9:E57. [PMID: 28587121 DOI: 10.3390/cancers9060057] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
257 Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337-343. [PMID: 23071247 DOI: 10.1200/jco.2012.43.2674] [Cited by in Crossref: 688] [Cited by in F6Publishing: 319] [Article Influence: 68.8] [Reference Citation Analysis]
258 Fathi Kazerooni A, Bagley SJ, Akbari H, Saxena S, Bagheri S, Guo J, Chawla S, Nabavizadeh A, Mohan S, Bakas S, Davatzikos C, Nasrallah MP. Applications of Radiomics and Radiogenomics in High-Grade Gliomas in the Era of Precision Medicine. Cancers (Basel) 2021;13:5921. [PMID: 34885031 DOI: 10.3390/cancers13235921] [Reference Citation Analysis]
259 Birkó Z, Nagy B, Klekner Á, Virga J. Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy. Int J Mol Sci 2020;21:E7522. [PMID: 33053907 DOI: 10.3390/ijms21207522] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
260 He Y, Kaina B. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? Int J Mol Sci 2019;20:E1562. [PMID: 30925722 DOI: 10.3390/ijms20071562] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
261 Wu M, Huang T, Wang J, Chen P, Mi W, Ying Y, Wang H, Zhao D, Huang S. Antilung cancer effect of ergosterol and cisplatin-loaded liposomes modified with cyclic arginine-glycine-aspartic acid and octa-arginine peptides. Medicine (Baltimore) 2018;97:e11916. [PMID: 30113492 DOI: 10.1097/MD.0000000000011916] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
262 Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 2015;17:45-52. [PMID: 25140036 DOI: 10.1093/neuonc/nou158] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 11.9] [Reference Citation Analysis]
263 Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 2009;11:69-79. [PMID: 18772354 DOI: 10.1215/15228517-2008-078] [Cited by in Crossref: 115] [Cited by in F6Publishing: 103] [Article Influence: 8.2] [Reference Citation Analysis]
264 Minea RO, Duc TC, Swenson SD, Cho HY, Huang M, Hartman H, Hofman FM, Schönthal AH, Chen TC. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. PLoS One 2020;15:e0238238. [PMID: 32881880 DOI: 10.1371/journal.pone.0238238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
265 de Almeida Sassi F, Lunardi Brunetto A, Schwartsmann G, Roesler R, Abujamra AL. Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche. J Oncol. 2012;2012:537861. [PMID: 22973309 DOI: 10.1155/2012/537861] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
266 Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L, Rastegar N, Vu V, Sánchez-Osuna M, Coulombe-Huntington J, Kanshin E, Whetstone H, Durand M, Thibault P, Hart K, Mangos M, Veyhl J, Chen W, Tran N, Duong BC, Aman AM, Che X, Lan X, Whitley O, Zaslaver O, Barsyte-Lovejoy D, Richards LM, Restall I, Caudy A, Röst HL, Bonday ZQ, Bernstein M, Das S, Cusimano MD, Spears J, Bader GD, Pugh TJ, Tyers M, Lupien M, Haibe-Kains B, Artee Luchman H, Weiss S, Massirer KB, Prinos P, Arrowsmith CH, Dirks PB. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun 2021;12:979. [PMID: 33579912 DOI: 10.1038/s41467-021-21204-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
267 Chamberlain MC. Neuro-oncology: a selected review of ASCO 2011 abstracts. Expert Rev Neurother 2011;11:1371-7. [PMID: 21955193 DOI: 10.1586/ern.11.104] [Reference Citation Analysis]
268 Belghali MY, Ba-M Hamed S, Admou B, Brahimi M, Khouchani M. [Epidemiological, clinical, therapeutic and evolutionary features of patients with glioblastoma: series of cases managed in the Department of Hematology-Oncology at the Mohammed VI University Hospital Center in Marrakech in 2016 and 2017]. Pan Afr Med J 2021;39:191. [PMID: 34603572 DOI: 10.11604/pamj.2021.39.191.28298] [Reference Citation Analysis]
269 Golebiewska A, Hau AC, Oudin A, Stieber D, Yabo YA, Baus V, Barthelemy V, Klein E, Bougnaud S, Keunen O, Wantz M, Michelucci A, Neirinckx V, Muller A, Kaoma T, Nazarov PV, Azuaje F, De Falco A, Flies B, Richart L, Poovathingal S, Arns T, Grzyb K, Mock A, Herold-Mende C, Steino A, Brown D, May P, Miletic H, Malta TM, Noushmehr H, Kwon YJ, Jahn W, Klink B, Tanner G, Stead LF, Mittelbronn M, Skupin A, Hertel F, Bjerkvig R, Niclou SP. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathol 2020;140:919-49. [PMID: 33009951 DOI: 10.1007/s00401-020-02226-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
270 Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer. 2014;14:747-753. [PMID: 25253389 DOI: 10.1038/nrc3819] [Cited by in Crossref: 174] [Cited by in F6Publishing: 153] [Article Influence: 21.8] [Reference Citation Analysis]
271 Su J, Long W, Ma Q, Xiao K, Li Y, Xiao Q, Peng G, Yuan J, Liu Q. Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas. Front Genet 2019;10:1143. [PMID: 31803233 DOI: 10.3389/fgene.2019.01143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
272 Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA 2009;302:276-89. [PMID: 19602687 DOI: 10.1001/jama.2009.1022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
273 Mercer RW, Tyler MA, Ulasov IV, Lesniak MS. Targeted therapies for malignant glioma: progress and potential. BioDrugs 2009;23:25-35. [PMID: 19344189 DOI: 10.2165/00063030-200923010-00003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
274 Sun MZ, Oh MC, Ivan ME, Kaur G, Safaee M, Kim JM, Phillips JJ, Auguste KI, Parsa AT. Current management of choroid plexus carcinomas. Neurosurg Rev 2014;37:179-92; discussion 192. [PMID: 24068529 DOI: 10.1007/s10143-013-0499-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
275 Rao S, Beckman RA, Riazi S, Yabar CS, Boca SM, Marshall JL, Pishvaian MJ, Brody JR, Madhavan S. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget 2017;8:37923-34. [PMID: 27888622 DOI: 10.18632/oncotarget.13544] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
276 Buczkowicz P, Hawkins C. Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. Front Oncol 2015;5:147. [PMID: 26175967 DOI: 10.3389/fonc.2015.00147] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
277 Jin F, Han GK, Zhang H, Zhang R, Li GH, Feng S, Qin XY, Kong LS, Nie QM, Li HR, Zhao L. Difference in the Inhibitory Effect of Temozolomide on TJ905 Glioma Cells and Stem Cells. Front Neurol 2017;8:474. [PMID: 28955297 DOI: 10.3389/fneur.2017.00474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
278 Johnson D, McKeever S, Stamatakos G, Dionysiou D, Graf N, Sakkalis V, Marias K, Wang Z, Deisboeck TS. Dealing with diversity in computational cancer modeling. Cancer Inform 2013;12:115-24. [PMID: 23700360 DOI: 10.4137/CIN.S11583] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
279 Gallo C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A. Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? J Neurooncol 2010;100:311-9. [PMID: 20556481 DOI: 10.1007/s11060-010-0168-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
280 Miranda SP, Baião FA, Fleck JL, Piccolo SR. Predicting drug sensitivity of cancer cells based on DNA methylation levels. PLoS One 2021;16:e0238757. [PMID: 34506489 DOI: 10.1371/journal.pone.0238757] [Reference Citation Analysis]
281 Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, Lawrence TS. Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. Cancer Res 2017;77:960-70. [PMID: 27923831 DOI: 10.1158/0008-5472.CAN-16-2008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
282 Liu Y, Li Q, Zhou L, Xie N, Nice EC, Zhang H, Huang C, Lei Y. Cancer drug resistance: redox resetting renders a way. Oncotarget 2016;7:42740-61. [PMID: 27057637 DOI: 10.18632/oncotarget.8600] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 19.3] [Reference Citation Analysis]
283 Heimer BW, Tam BE, Sikes HD. Characterization and directed evolution of a methyl-binding domain protein for high-sensitivity DNA methylation analysis. Protein Eng Des Sel 2015;28:543-51. [PMID: 26384511 DOI: 10.1093/protein/gzv046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
284 Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. 2015;3:95. [PMID: 26015937 DOI: 10.3978/j.issn.2305-5839.2015.03.57] [Cited by in F6Publishing: 47] [Reference Citation Analysis]
285 Zinn PO, Mahajan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, Colen RR. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011;6:e25451. [PMID: 21998659 DOI: 10.1371/journal.pone.0025451] [Cited by in Crossref: 192] [Cited by in F6Publishing: 174] [Article Influence: 17.5] [Reference Citation Analysis]
286 Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT, Kupper MD, Neal D, Nabilsi NH, Kladde MP, Suslov O, Brabletz S, Brabletz T, Reynolds BA, Steindler DA. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 2013;5:1196-212. [PMID: 23818228 DOI: 10.1002/emmm.201302827] [Cited by in Crossref: 224] [Cited by in F6Publishing: 220] [Article Influence: 24.9] [Reference Citation Analysis]
287 Wu Q, Berglund AE, Etame AB. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. Int J Mol Sci 2021;22:8324. [PMID: 34361090 DOI: 10.3390/ijms22158324] [Reference Citation Analysis]
288 Boyd NH, Walker K, Fried J, Hackney JR, McDonald PC, Benavides GA, Spina R, Audia A, Scott SE, Libby CJ, Tran AN, Bevensee MO, Griguer C, Nozell S, Gillespie GY, Nabors B, Bhat KP, Bar EE, Darley-Usmar V, Xu B, Gordon E, Cooper SJ, Dedhar S, Hjelmeland AB. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight 2017;2:92928. [PMID: 29263302 DOI: 10.1172/jci.insight.92928] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 10.4] [Reference Citation Analysis]
289 Hofer S, Rushing E, Preusser M, Marosi C. Molecular biology of high-grade gliomas: what should the clinician know? Chin J Cancer 2014;33:4-7. [PMID: 24325789 DOI: 10.5732/cjc.013.10218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
290 Yoo B, Ifediba MA, Ghosh S, Medarova Z, Moore A. Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ. Mol Imaging Biol 2014;16:680-9. [PMID: 24696184 DOI: 10.1007/s11307-014-0734-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
291 Björklund P, Pacak K, Crona J. Precision medicine in pheochromocytoma and paraganglioma: current and future concepts. J Intern Med 2016;280:559-73. [PMID: 27165774 DOI: 10.1111/joim.12507] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
292 Castro GN, Cayado-Gutiérrez N, Moncalero VL, Lima P, De Angelis RL, Chávez V, Cuello-Carrión FD, Ciocca DR. Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas. Cell Stress Chaperones 2012;17:779-90. [PMID: 22806482 DOI: 10.1007/s12192-012-0350-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
293 Ferreyra Vega S, Olsson Bontell T, Corell A, Smits A, Jakola AS, Carén H. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clin Epigenetics 2021;13:102. [PMID: 33941250 DOI: 10.1186/s13148-021-01085-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Cagney DN, Sul J, Huang RY, Ligon KL, Wen PY, Alexander BM. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro Oncol. 2018;20:1162-1172. [PMID: 29294069 DOI: 10.1093/neuonc/nox242] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
295 Schweneker K, Clemm C, Brügel M, Souvatzoglou M, Hermisson M, Schmidt-Graf F, Zimmer C, Peschel C, Jost PJ. Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature. Exp Hematol Oncol 2014;3:29. [PMID: 25954595 DOI: 10.1186/2162-3619-3-29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
296 Himes BT, Geiger PA, Ayasoufi K, Bhargav AG, Brown DA, Parney IF. Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. Front Oncol 2021;11:770561. [PMID: 34778089 DOI: 10.3389/fonc.2021.770561] [Reference Citation Analysis]
297 Schmidt L, Kling T, Monsefi N, Olsson M, Hansson C, Baskaran S, Lundgren B, Martens U, Häggblad M, Westermark B, Forsberg Nilsson K, Uhrbom L, Karlsson-Lindahl L, Gerlee P, Nelander S. Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Neuro Oncol 2013;15:1469-78. [PMID: 24101737 DOI: 10.1093/neuonc/not111] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
298 Head RJ, Fay MF, Cosgrove L, Y C Fung K, Rundle-Thiele D, Martin JH. Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma. Cancer Biol Ther 2017;18:917-26. [PMID: 29020502 DOI: 10.1080/15384047.2017.1385680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
299 Djuric U, Lam KHB, Kao J, Batruch I, Jevtic S, Papaioannou MD, Diamandis P. Defining Protein Pattern Differences Among Molecular Subtypes of Diffuse Gliomas Using Mass Spectrometry. Mol Cell Proteomics 2019;18:2029-43. [PMID: 31353322 DOI: 10.1074/mcp.RA119.001521] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
300 Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, Brem H, Quiñones-Hinojosa A. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 2011;18:239-45. [PMID: 20697823 DOI: 10.1245/s10434-010-1242-6] [Cited by in Crossref: 92] [Cited by in F6Publishing: 86] [Article Influence: 7.7] [Reference Citation Analysis]
301 Duan J, Huang W, Shi H. Positive expression of KIF20A indicates poor prognosis of glioma patients. Onco Targets Ther 2016;9:6741-9. [PMID: 27843327 DOI: 10.2147/OTT.S115974] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
302 Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol 2013;125:621-36. [PMID: 23512379 DOI: 10.1007/s00401-013-1106-9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
303 Yuan C, Chen H, Tu S, Huang HY, Pan Y, Gui X, Kuang M, Shen X, Zheng Q, Zhang Y, Cheng C, Hong H, Tao X, Peng Y, Yao X, Meng F, Ji H, Shao Z, Sun Y. A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks. Genome Biol 2021;22:156. [PMID: 34001209 DOI: 10.1186/s13059-021-02376-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Jack J, Havener TM, McLeod HL, Motsinger-Reif AA, Foster M. Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations. Pharmacogenomics 2015;16:1451-63. [PMID: 26314407 DOI: 10.2217/PGS.15.85] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
305 Auer TA, Kern M, Fehrenbach U, Tanyldizi Y, Misch M, Wiener E. T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma. Neuroradiol J 2021;34:392-400. [PMID: 33573473 DOI: 10.1177/1971400921989325] [Reference Citation Analysis]
306 Mak KS, Agarwal A, Qureshi MM, Truong MT. Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. Cancer Med 2017;6:1192-200. [PMID: 28440040 DOI: 10.1002/cam4.1070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
307 Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. EPMA position paper in cancer: current overview and future perspectives. EPMA J 2015;6:9. [PMID: 25908947 DOI: 10.1186/s13167-015-0030-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
308 Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int J Mol Sci 2019;20:E4781. [PMID: 31561483 DOI: 10.3390/ijms20194781] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 22.3] [Reference Citation Analysis]
309 Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, Bui Y, Stream A, McBride WH, Liau LM, Nelson SF, Cloughesy TF, Yong WH, Lai A, Tso CL. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Mol Cancer 2015;14:189. [PMID: 26546412 DOI: 10.1186/s12943-015-0459-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
310 Shirai K, Chakravarti A. Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther 2011;11:1935-44. [PMID: 22117160 DOI: 10.1586/era.11.103] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
311 Kirstein A, Schmid TE, Combs SE. The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme. Cancers (Basel) 2020;12:E1099. [PMID: 32354046 DOI: 10.3390/cancers12051099] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
312 Jalali R, Rishi A, Goda JS, Sridhar E, Gurav M, Sharma P, Moiyadi A, Shetty P, Gupta T. Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children. Neurooncol Pract 2016;3:39-47. [PMID: 31579520 DOI: 10.1093/nop/npv024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
313 Jesionek-Kupnicka D, Braun M, Trąbska-Kluch B, Czech J, Szybka M, Szymańska B, Kulczycka-Wojdala D, Bieńkowski M, Kordek R, Zawlik I. MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients. Arch Med Sci 2019;15:504-12. [PMID: 30899304 DOI: 10.5114/aoms.2017.69374] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
314 Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 2014;5:5674-85. [PMID: 25010037 DOI: 10.18632/oncotarget.2158] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 15.9] [Reference Citation Analysis]
315 Thomas KEH, Voros BA, Boudreaux JP, Thiagarajan R, Woltering EA, Ramirez RA. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. Oncologist. 2019;24:1076-1088. [PMID: 30635447 DOI: 10.1634/theoncologist.2018-0604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
316 Ozdemir-Kaynak E, Qutub AA, Yesil-Celiktas O. Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy. Front Physiol 2018;9:170. [PMID: 29615917 DOI: 10.3389/fphys.2018.00170] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 16.8] [Reference Citation Analysis]
317 Cavanagh TT, Holle LM. Potential new gene therapy option with sitimagene ceradenovec for newly diagnosed patients with glioblastoma multiforme. Cancer Biol Ther 2014;15:263-5. [PMID: 24352098 DOI: 10.4161/cbt.27326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
318 White A, Fabian V, McDonald K, Nowak AK. Compliance with reporting guidelines by Australian pathologists: an audit of the quality of histopathology reporting in high-grade glioma. Neurooncol Pract 2016;3:97-104. [PMID: 31386085 DOI: 10.1093/nop/npv033] [Reference Citation Analysis]
319 Zhai B, Li Y, Kotapalli SS, Bacha J, Brown D, Steinø A, Daugaard M. Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells. Cell Death Dis 2020;11:577. [PMID: 32709853 DOI: 10.1038/s41419-020-02780-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
320 Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol 2015;17 Suppl 6:vi1-26. [PMID: 26403167 DOI: 10.1093/neuonc/nov169] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
321 Barz M, Gerhardt J, Bette S, Aftahy AK, Huber T, Combs SE, Ryang YM, Wiestler B, Skardelly M, Gepfner-Tuma I, Behling F, Schmidt-Graf F, Meyer B, Gempt J. Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale - a bicentric retrospective study. BMC Neurol 2021;21:446. [PMID: 34781889 DOI: 10.1186/s12883-021-02424-0] [Reference Citation Analysis]
322 Yan VC, Butterfield HE, Poral AH, Yan MJ, Yang KL, Pham CD, Muller FL. Why Great Mitotic Inhibitors Make Poor Cancer Drugs. Trends Cancer 2020;6:924-41. [PMID: 32536592 DOI: 10.1016/j.trecan.2020.05.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
323 Zhao Z, Liu M, Long W, Yuan J, Li H, Zhang C, Tang G, Jiang W, Yuan X, Wu M, Liu Q. Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma. Cancer Cell Int 2021;21:456. [PMID: 34454479 DOI: 10.1186/s12935-021-02153-x] [Reference Citation Analysis]
324 Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 2007;282:21206-12. [PMID: 17513297 DOI: 10.1074/jbc.M703042200] [Cited by in Crossref: 155] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
325 Kusumawidjaja G, Gan PZ, Ong WS, Teyateeti A, Dankulchai P, Tan DY, Chua ET, Chua KL, Tham CK, Wong FY, Chua ML. Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. Onco Targets Ther 2016;9:1115-22. [PMID: 27042103 DOI: 10.2147/OTT.S96509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
326 Hagemann C, Neuhaus N, Dahlmann M, Kessler AF, Kobelt D, Herrmann P, Eyrich M, Freitag B, Linsenmann T, Monoranu CM, Ernestus RI, Löhr M, Stein U. Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response. Cancers (Basel) 2019;11:E825. [PMID: 31200581 DOI: 10.3390/cancers11060825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
327 Freitas M, Malheiros S, Stávale JN, Biassi TP, Zamunér FT, de Souza Begnami M, Soares FA, Vettore AL. Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget 2013;4:636-46. [PMID: 23592437 DOI: 10.18632/oncotarget.950] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
328 Shriwas O, Mohapatra P, Mohanty S, Dash R. The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy. Front Oncol 2020;10:612337. [PMID: 33718113 DOI: 10.3389/fonc.2020.612337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
329 Estival A, Sanz C, Ramirez JL, Velarde JM, Domenech M, Carrato C, de Las Peñas R, Gil-Gil M, Sepúlveda J, Armengol R, Cardiel I, Berrocal A, Luque R, Herrero A, Balana C. Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. Sci Rep 2019;9:11125. [PMID: 31366977 DOI: 10.1038/s41598-019-47642-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
330 Bidinotto LT, Torrieri R, Mackay A, Almeida GC, Viana-Pereira M, Cruvinel-Carloni A, Spina ML, Campanella NC, Pereira de Menezes W, Clara CA, Becker AP, Jones C, Reis RM. Copy Number Profiling of Brazilian Astrocytomas. G3 (Bethesda) 2016;6:1867-78. [PMID: 27172220 DOI: 10.1534/g3.116.029884] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
331 Zygogianni A, Protopapa M, Kougioumtzopoulou A, Simopoulou F, Nikoloudi S, Kouloulias V. From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence. Clin Transl Oncol 2018;20:989-1003. [PMID: 29335830 DOI: 10.1007/s12094-018-1831-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
332 Yang H, Wei D, Yang K, Tang W, Luo Y, Zhang J. The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis. Neurochem Res 2014;39:2277-87. [PMID: 25230908 DOI: 10.1007/s11064-014-1435-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
333 Cimini A, Ippoliti R. Innovative Therapies against Human Glioblastoma Multiforme. ISRN Oncol 2011;2011:787490. [PMID: 22091432 DOI: 10.5402/2011/787490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
334 Drukala J, Urbanska K, Wilk A, Grabacka M, Wybieralska E, Del Valle L, Madeja Z, Reiss K. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro. Mol Cancer 2010;9:159. [PMID: 20569465 DOI: 10.1186/1476-4598-9-159] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
335 Nadkarni A, Shrivastav M, Mladek AC, Schwingler PM, Grogan PT, Chen J, Sarkaria JN. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J Neurooncol 2012;110:349-57. [PMID: 23054561 DOI: 10.1007/s11060-012-0979-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
336 Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008;18:520-32. [PMID: 18400046 DOI: 10.1111/j.1750-3639.2008.00153.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 80] [Article Influence: 1.2] [Reference Citation Analysis]
337 Lawrence YR, Werner-Wasik M, Dicker AP. Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncol 2008;4:689-704. [PMID: 18922126 DOI: 10.2217/14796694.4.5.689] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
338 Hölzl D, Hutarew G, Zellinger B, Schlicker HU, Schwartz C, Winkler PA, Sotlar K, Kraus TFJ. Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma. J Cancer Res Clin Oncol 2021;147:2271-80. [PMID: 33963441 DOI: 10.1007/s00432-021-03656-w] [Reference Citation Analysis]
339 Brown MP, Ebert LM, Gargett T. Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. Clin Transl Immunology 2019;8:e1050. [PMID: 31139410 DOI: 10.1002/cti2.1050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
340 Choi HJ, Choi SH, You SH, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Park CK, Park SH. MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features. AJNR Am J Neuroradiol 2021;42:853-60. [PMID: 33632732 DOI: 10.3174/ajnr.A7004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Rathore S, Akbari H, Rozycki M, Abdullah KG, Nasrallah MP, Binder ZA, Davuluri RV, Lustig RA, Dahmane N, Bilello M, O'Rourke DM, Davatzikos C. Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Sci Rep 2018;8:5087. [PMID: 29572492 DOI: 10.1038/s41598-018-22739-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 17.0] [Reference Citation Analysis]
342 Elson A, Paulson E, Bovi J, Siker M, Schultz C, Laviolette PS. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme. J Neurooncol 2015;123:179-88. [PMID: 25894597 DOI: 10.1007/s11060-015-1782-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
343 Mathew LK, Huangyang P, Mucaj V, Lee SS, Skuli N, Eisinger-Mathason TS, Biju K, Li B, Venneti S, Lal P, Lathia JD, Rich JN, Keith B, Simon MC. Feedback circuitry between miR-218 repression and RTK activation in glioblastoma. Sci Signal 2015;8:ra42. [PMID: 25943352 DOI: 10.1126/scisignal.2005978] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
344 Lin J, Kennedy SH, Svarovsky T, Rogers J, Kemnitz JW, Xu A, Zondervan KT. High-quality genomic DNA extraction from formalin-fixed and paraffin-embedded samples deparaffinized using mineral oil. Anal Biochem. 2009;395:265-267. [PMID: 19698695 DOI: 10.1016/j.ab.2009.08.016] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]
345 deSouza RM, Shaweis H, Han C, Sivasubramaniam V, Brazil L, Beaney R, Sadler G, Al-Sarraj S, Hampton T, Logan J, Hurwitz V, Bhangoo R, Gullan R, Ashkan K. Has the survival of patients with glioblastoma changed over the years? Br J Cancer 2016;114:146-50. [PMID: 26671748 DOI: 10.1038/bjc.2015.421] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
346 Schaff LR, Lassman AB. Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas? Semin Radiat Oncol 2015;25:203-9. [PMID: 26050591 DOI: 10.1016/j.semradonc.2015.02.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
347 Yanagihara TK, Grinband J, Rowley J, Cauley KA, Lee A, Garrett M, Afghan M, Chu A, Wang TJC. A Simple Automated Method for Detecting Recurrence in High-Grade Glioma. AJNR Am J Neuroradiol 2016;37:2019-25. [PMID: 27418469 DOI: 10.3174/ajnr.A4873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
348 Fang H, Shi R, Chen D, Qu Y, Wu Q, Yang X, Lu X, Zhang CW, Li L, Lim KL. Intramolecular charge transfer enhancing strategy based MAO-A specific two-photon fluorescent probes for glioma cell/tissue imaging. Chem Commun (Camb) 2021;57:11260-3. [PMID: 34636370 DOI: 10.1039/d1cc04744b] [Reference Citation Analysis]
349 Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol 2010;12:1167-72. [PMID: 20729242 DOI: 10.1093/neuonc/noq100] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
350 Ochsenbein AF, Schubert AD, Vassella E, Mariani L. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Neurooncol 2011;103:343-51. [PMID: 20857319 DOI: 10.1007/s11060-010-0395-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
351 Mosrati MA, Malmström A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthäll C, Strandéus M, Stenmark-Askmalm M, Söderkvist P. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2015;6:16663-73. [PMID: 26143636 DOI: 10.18632/oncotarget.4389] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 10.5] [Reference Citation Analysis]
352 Toffolatti L, Scquizzato E, Cavallin S, Canal F, Scarpa M, Stefani PM, Gherlinzoni F, Dei Tos AP. MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma. Virchows Arch 2014;465:579-86. [PMID: 25031012 DOI: 10.1007/s00428-014-1622-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
353 Azam Z, To ST, Tannous BA. Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance. Adv Sci (Weinh) 2020;7:2002015. [PMID: 33240762 DOI: 10.1002/advs.202002015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
354 Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, Benson A, Woods AM, Cher L. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro Oncol 2010;12:500-7. [PMID: 20406900 DOI: 10.1093/neuonc/nop065] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
355 Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N. Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol Rev. 2018;70:412-445. [PMID: 29669750 DOI: 10.1124/pr.117.014944] [Cited by in Crossref: 227] [Cited by in F6Publishing: 223] [Article Influence: 56.8] [Reference Citation Analysis]
356 Ishiguro K, Shyam K, Penketh PG, Sartorelli AC. Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the protein. Anal Biochem 2008;383:44-51. [PMID: 18783719 DOI: 10.1016/j.ab.2008.08.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
357 Le Rhun E, Rhun EL, Taillibert S, Chamberlain MC. The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int 2015;6:S9-S44. [PMID: 25722939 DOI: 10.4103/2152-7806.151331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
358 Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A, Milin S, Wager M, Sorel N, Guilhot J. A mesenchymal glioma stem cell profile is related to clinical outcome. Oncogenesis. 2014;3:e91. [PMID: 24637491 DOI: 10.1038/oncsis.2014.5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
359 Hirono S, Hasegawa Y, Sakaida T, Uchino Y, Hatano K, Iuchi T. Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. Sci Rep 2019;9:17794. [PMID: 31780768 DOI: 10.1038/s41598-019-54398-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
360 Manzanares D, Pérez-Carrión MD, Jiménez Blanco JL, Ortiz Mellet C, García Fernández JM, Ceña V. Cyclodextrin-Based Nanostructure Efficiently Delivers siRNA to Glioblastoma Cells Preferentially via Macropinocytosis. Int J Mol Sci 2020;21:E9306. [PMID: 33291321 DOI: 10.3390/ijms21239306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
361 Geiger GA, Fu W, Kao GD. Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system. Cancer Res 2008;68:3396-404. [PMID: 18451167 DOI: 10.1158/0008-5472.CAN-07-6396] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
362 Alassiri AH, Alkhaibary A, Al-Sarheed S, Alsufani F, Alharbi M, Alkhani A, Aloraidi A. O6-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma. Ann Saudi Med 2019;39:410-6. [PMID: 31804140 DOI: 10.5144/0256-4947.2019.410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
363 Lillehei KO, Kalkanis SN, Liau LM, Mydland DE, Olson J, Paleologos NA, Ryken T, Johnson T, Scullin E. Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncol 2018;7:CNS08. [PMID: 29206049 DOI: 10.2217/cns-2017-0036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
364 Brognaro E. The inverse paradigm and the ancestral cell of IDH-wildtype glioblastoma. Clin Transl Oncol 2021. [PMID: 34152549 DOI: 10.1007/s12094-021-02663-0] [Reference Citation Analysis]
365 Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P, Gardiman M, Labianca R, Bianchini C, Ermani M, Reni M. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 2009;64:769-75. [PMID: 19169684 DOI: 10.1007/s00280-009-0926-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
366 D'Alimonte I, Nargi E, Zuccarini M, Lanuti P, Di Iorio P, Giuliani P, Ricci-Vitiani L, Pallini R, Caciagli F, Ciccarelli R. Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells. Purinergic Signal 2015;11:331-46. [PMID: 25976165 DOI: 10.1007/s11302-015-9454-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
367 Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun. 2014;455:43-57. [PMID: 25128828 DOI: 10.1016/j.bbrc.2014.08.001] [Cited by in Crossref: 100] [Cited by in F6Publishing: 98] [Article Influence: 12.5] [Reference Citation Analysis]
368 van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, Sminia P. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 2010;103:29-35. [PMID: 20517307 DOI: 10.1038/sj.bjc.6605712] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
369 Rasul FT, Watts C. Novel Surgical Approaches to High-Grade Gliomas. Curr Treat Options Neurol 2015;17:369. [PMID: 26178621 DOI: 10.1007/s11940-015-0369-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
370 Woodhouse C, Ward T, Gaskill-Shipley M, Chaudhary R. Feasibility of a modified Atkins diet in glioma patients during radiation and its effect on radiation sensitization. Curr Oncol 2019;26:e433-8. [PMID: 31548811 DOI: 10.3747/co.26.4889] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
371 Lin N, Li W, Wang X, Hou S, Yu D, Zhao X, Jin C, Yao G, Yan W, You Y. Upregulation of miR-340 Inhibits Tumor Growth and Mesenchymal Transition via Targeting c-MET in Glioblastoma. Cancer Manag Res 2020;12:3343-52. [PMID: 32494198 DOI: 10.2147/CMAR.S250772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
372 Kahlert UD, Suwala AK, Raabe EH, Siebzehnrubl FA, Suarez MJ, Orr BA, Bar EE, Maciaczyk J, Eberhart CG. ZEB1 Promotes Invasion in Human Fetal Neural Stem Cells and Hypoxic Glioma Neurospheres. Brain Pathol 2015;25:724-32. [PMID: 25521330 DOI: 10.1111/bpa.12240] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
373 Hashimoto K, Narita Y, Matsushita Y, Miyakita Y, Ono M, Kayama T, Shibui S. Methylation status of O6-methylguanine-DNA-methyl transferase promoter region in non-small-cell lung cancer patients with brain metastasis. Clin Transl Oncol 2012;14:31-5. [PMID: 22262716 DOI: 10.1007/s12094-012-0758-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
374 Jungk C, Chatziaslanidou D, Ahmadi R, Capper D, Bermejo JL, Exner J, von Deimling A, Herold-Mende C, Unterberg A. Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. BMC Cancer 2016;16:81. [PMID: 26865253 DOI: 10.1186/s12885-016-2131-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
375 Wenger KJ, Wagner M, You SJ, Franz K, Harter PN, Burger MC, Voss M, Ronellenfitsch MW, Fokas E, Steinbach JP, Bähr O. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol Lett 2017;14:1141-6. [PMID: 28693286 DOI: 10.3892/ol.2017.6251] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
376 Ko KK, Lee ES, Joe YA, Hong YK. Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells. Exp Ther Med 2011;2:343-8. [PMID: 22977508 DOI: 10.3892/etm.2011.207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
377 Haynes HR, Camelo-Piragua S, Kurian KM. Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. Front Oncol 2014;4:47. [PMID: 24716189 DOI: 10.3389/fonc.2014.00047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
378 Sarkisjan D, Julsing JR, El Hassouni B, Honeywell RJ, Kathmann I, Matherly LH, Lee YB, Kim DJ, Peters GJ. RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier. Int J Mol Sci 2020;21:E2717. [PMID: 32295203 DOI: 10.3390/ijms21082717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
379 Xu S, Tang L, Liu Z, Yang K, Cheng Q. Bioinformatic Analyses Identify a Prognostic Autophagy-Related Long Non-coding RNA Signature Associated With Immune Microenvironment in Diffuse Gliomas. Front Cell Dev Biol 2021;9:694633. [PMID: 34211979 DOI: 10.3389/fcell.2021.694633] [Reference Citation Analysis]
380 Lesimple T, Riffaud L, Frappaz D, Ben Hassel M, Gédouin D, Bay JO, Linassier C, Hamlat A, Piot G, Fabbro M, Saïkali S, Carsin B, Guégan Y. Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study. J Neurooncol 2009;93:253-60. [PMID: 19139825 DOI: 10.1007/s11060-008-9774-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
381 Drumm MR, Dixit KS, Grimm S, Kumthekar P, Lukas RV, Raizer JJ, Stupp R, Chheda MG, Kam KL, McCord M, Sachdev S, Kruser T, Steffens A, Javier R, McCortney K, Horbinski C. Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro Oncol 2020;22:470-9. [PMID: 31711239 DOI: 10.1093/neuonc/noz216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
382 Moon WJ, Choi JW, Roh HG, Lim SD, Koh YC. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology 2012;54:555-63. [PMID: 21833736 DOI: 10.1007/s00234-011-0947-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
383 Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M. Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. J Neurooncol 2011;105:337-44. [PMID: 21520004 DOI: 10.1007/s11060-011-0595-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
384 Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 2013;15:930-5. [PMID: 23553268 DOI: 10.1093/neuonc/not040] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
385 Philip-Ephraim EE, Eyong KI, Williams UE, Ephraim RP. The role of radiotherapy and chemotherapy in the treatment of primary adult high grade gliomas: assessment of patients for these treatment approaches and the common immediate side effects. ISRN Oncol 2012;2012:902178. [PMID: 23304556 DOI: 10.5402/2012/902178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
386 Feng J, Zhang Y, She X, Sun Y, Fan L, Ren X, Fu H, Liu C, Li P, Zhao C, Liu Q, Liu Q, Li G, Wu M. Hypermethylated gene ANKDD1A is a candidate tumor suppressor that interacts with FIH1 and decreases HIF1α stability to inhibit cell autophagy in the glioblastoma multiforme hypoxia microenvironment. Oncogene 2019;38:103-19. [DOI: 10.1038/s41388-018-0423-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
387 Welch M, Lai R. Glioblastoma multiforme. Curr Treat Options Neurol 2009;11:297-305. [PMID: 19523355 DOI: 10.1007/s11940-009-0033-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
388 Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009;27:579-84. [PMID: 19075262 DOI: 10.1200/JCO.2008.18.9639] [Cited by in Crossref: 253] [Cited by in F6Publishing: 144] [Article Influence: 18.1] [Reference Citation Analysis]
389 Cheng G, Zhang X, Tang HF, Zhang Y, Zhang XH, Cao WD, Gao DK, Wang XL, Jin BQ. Asterosaponin 1, a cytostatic compound from the starfish Culcita novaeguineae, functions by inducing apoptosis in human glioblastoma U87MG cells. J Neurooncol 2006;79:235-41. [PMID: 16628475 DOI: 10.1007/s11060-006-9136-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
390 Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8. [PMID: 18182667 DOI: 10.1200/JCO.2007.13.3652] [Cited by in Crossref: 205] [Cited by in F6Publishing: 113] [Article Influence: 14.6] [Reference Citation Analysis]
391 Zhang GB, Cui XL, Sui DL, Ren XH, Zhang Z, Wang ZC, Lin S. Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. J Neurooncol 2013;113:251-8. [PMID: 23494873 DOI: 10.1007/s11060-013-1102-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
392 Yasaka K, Akai H, Kunimatsu A, Kiryu S, Abe O. Deep learning with convolutional neural network in radiology. Jpn J Radiol. 2018;36:257-272. [PMID: 29498017 DOI: 10.1007/s11604-018-0726-3] [Cited by in Crossref: 93] [Cited by in F6Publishing: 68] [Article Influence: 23.3] [Reference Citation Analysis]
393 Johnson DR, Galanis E. Incorporation of prognostic and predictive factors into glioma clinical trials. Curr Oncol Rep 2013;15:56-63. [PMID: 23125011 DOI: 10.1007/s11912-012-0279-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
394 Kurdi M, Shafique Butt N, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, Saeedi R, Al-Sinani T, Alghanmi N, Bari MO, Samkari A, Lary AI. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents. Pathol Oncol Res 2021;27:1609778. [PMID: 34257620 DOI: 10.3389/pore.2021.1609778] [Reference Citation Analysis]
395 Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH. Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 2012;107:643-50. [PMID: 22270848 DOI: 10.1007/s11060-011-0790-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
396 Whisenhunt TR Jr, Rajneesh KF, Hackney JR, Markert JM. Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. Oncolytic Virother 2015;4:33-8. [PMID: 27512668 DOI: 10.2147/OV.S62461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
397 Chi HC, Tsai CY, Tsai MM, Lin KH. Impact of DNA and RNA Methylation on Radiobiology and Cancer Progression. Int J Mol Sci 2018;19:E555. [PMID: 29439529 DOI: 10.3390/ijms19020555] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
398 Richard S, Tachon G, Milin S, Wager M, Karayan-Tapon L. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma. Cancer Med 2020;9:6344-53. [PMID: 32666673 DOI: 10.1002/cam4.3217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
399 Weller M, Preusser M. How we treat patients with brain tumour during the COVID-19 pandemic. ESMO Open 2020;4:e000789. [PMID: 32409298 DOI: 10.1136/esmoopen-2020-000789] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
400 Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 2009;11:109-21. [PMID: 18682579 DOI: 10.1215/15228517-2008-060] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis]
401 Shen D, Liu T, Lin Q, Lu X, Wang Q, Lin F, Mao W. MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study. PLoS One 2014;9:e107558. [PMID: 25211033 DOI: 10.1371/journal.pone.0107558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
402 Wait SD, Prabhu RS, Burri SH, Atkins TG, Asher AL. Polymeric drug delivery for the treatment of glioblastoma. Neuro Oncol 2015;17 Suppl 2:ii9-ii23. [PMID: 25746091 DOI: 10.1093/neuonc/nou360] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
403 Luedi MM, Singh SK, Mosley JC, Hatami M, Gumin J, Sulman EP, Lang FF, Stueber F, Zinn PO, Colen RR. A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients. J Neurosurg Anesthesiol 2017;29:46-58. [PMID: 27653222 DOI: 10.1097/ANA.0000000000000368] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
404 Robinson W, Sharan R, Leiserson MDM. Modeling clinical and molecular covariates of mutational process activity in cancer. Bioinformatics 2019;35:i492-500. [PMID: 31510643 DOI: 10.1093/bioinformatics/btz340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
405 Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012;3:1112-1123. [PMID: 23047041 DOI: 10.18632/oncotarget.604] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 9.4] [Reference Citation Analysis]
406 Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, Kitange GJ, He L, Hu Z, Parney IF, Meyer FB, Giannini C, Sarkaria JN, Zhang Z. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 2018;9:2949. [PMID: 30054476 DOI: 10.1038/s41467-018-05373-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 20.8] [Reference Citation Analysis]
407 Eisenstat DD, Pollack IF, Demers A, Sapp MV, Lambert P, Weisfeld-Adams JD, Burger PC, Gilles F, Davis RL, Packer R, Boyett JM, Finlay JL. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. J Neurooncol 2015;121:573-81. [PMID: 25431150 DOI: 10.1007/s11060-014-1669-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
408 Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY. Imaging Biomarkers in Immunotherapy. Biomark Cancer 2016;8:1-13. [PMID: 26949344 DOI: 10.4137/BIC.S31805] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
409 Yu W, Zhang L, Wei Q, Shao A. O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy. Front Oncol 2019;9:1547. [PMID: 32010632 DOI: 10.3389/fonc.2019.01547] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
410 Spence AM, Kiem HP, Partap S, Schuetze S, Silber JR, Peterson RA. Complications of a temozolomide overdose: a case report. J Neurooncol 2006;80:57-61. [PMID: 16645714 DOI: 10.1007/s11060-006-9152-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
411 Ha SY, Kang SY, Do IG, Suh YL. Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. J Neurooncol 2013;112:439-48. [PMID: 23412777 DOI: 10.1007/s11060-013-1073-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
412 Li J, Hu X, Luo T, Lu Y, Feng Y, Zhang H, Liu D, Fan X, Wang Y, Jiang L, Wang Y, Hao X, Shi T, Wang Z. N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation. Eur J Med Chem 2021;226:113817. [PMID: 34537445 DOI: 10.1016/j.ejmech.2021.113817] [Reference Citation Analysis]
413 Li SZ, Hu YY, Zhao JL, Zang J, Fei Z, Han H, Qin HY. Downregulation of FHL1 protein in glioma inhibits tumor growth through PI3K/AKT signaling. Oncol Lett 2020;19:3781-8. [PMID: 32382330 DOI: 10.3892/ol.2020.11476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
414 Floyd DH, Zhang Y, Dey BK, Kefas B, Breit H, Marks K, Dutta A, Herold-Mende C, Synowitz M, Glass R, Abounader R, Purow BW. Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim. PLoS One 2014;9:e96239. [PMID: 24805821 DOI: 10.1371/journal.pone.0096239] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 8.4] [Reference Citation Analysis]
415 Reynés G, Vila V, Fleitas T, Reganon E, Font de Mora J, Jordá M, Martínez-Sales V. Circulating endothelial cells and procoagulant microparticles in patients with glioblastoma: prognostic value. PLoS One 2013;8:e69034. [PMID: 23922679 DOI: 10.1371/journal.pone.0069034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
416 Chae Y, Roh J, Kim W. The Roles Played by Long Non-Coding RNAs in Glioma Resistance. Int J Mol Sci 2021;22:6834. [PMID: 34202078 DOI: 10.3390/ijms22136834] [Reference Citation Analysis]
417 Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 2015;38:E6. [PMID: 25552286 DOI: 10.3171/2014.10.FOCUS12367] [Cited by in Crossref: 156] [Cited by in F6Publishing: 102] [Article Influence: 22.3] [Reference Citation Analysis]
418 Yogananda CGB, Shah BR, Nalawade SS, Murugesan GK, Yu FF, Pinho MC, Wagner BC, Mickey B, Patel TR, Fei B, Madhuranthakam AJ, Maldjian JA. MRI-Based Deep-Learning Method for Determining Glioma MGMT Promoter Methylation Status. AJNR Am J Neuroradiol 2021;42:845-52. [PMID: 33664111 DOI: 10.3174/ajnr.A7029] [Reference Citation Analysis]
419 De Meyer T, Bady P, Trooskens G, Kurscheid S, Bloch J, Kros JM, Hainfellner JA, Stupp R, Delorenzi M, Hegi ME, Van Criekinge W. Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison. Sci Rep 2015;5:15375. [PMID: 26482909 DOI: 10.1038/srep15375] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
420 Xavier MA, Rezende F, Titze-de-Almeida R, Cornelissen B. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme. Biomolecules 2021;11:1188. [PMID: 34439854 DOI: 10.3390/biom11081188] [Reference Citation Analysis]
421 Byun HK, Kim N, Yoon HI, Kang SG, Kim SH, Cho J, Baek JG, Chang JH, Suh CO. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Radiat Oncol 2019;14:51. [PMID: 30917849 DOI: 10.1186/s13014-019-1256-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
422 Yoshioka M, Matsutani T, Hara A, Hirono S, Hiwasa T, Takiguchi M, Iwadate Y. Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma. Oncotarget 2018;9:27728-35. [PMID: 29963232 DOI: 10.18632/oncotarget.25543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
423 Moinuddin FM, Hirano H, Shinsato Y, Higa N, Arita K, Furukawa T. ATP7B expression in human glioblastoma is related to temozolomide resistance. Oncol Lett 2017;14:7777-82. [PMID: 29250175 DOI: 10.3892/ol.2017.7249] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
424 Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 2012;18:4070-9. [PMID: 22675172 DOI: 10.1158/1078-0432.CCR-12-0560] [Cited by in Crossref: 83] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
425 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009;27:1262-7. [PMID: 19204199 DOI: 10.1200/JCO.2008.18.8417] [Cited by in Crossref: 195] [Cited by in F6Publishing: 106] [Article Influence: 15.0] [Reference Citation Analysis]
426 Schaff LR, Yan D, Thyparambil S, Tian Y, Cecchi F, Rosenblum M, Reiner AS, Panageas KS, Hembrough T, Lin AL. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. J Neurooncol 2020;146:163-70. [PMID: 31823165 DOI: 10.1007/s11060-019-03358-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
427 Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci 2012;103:587-92. [PMID: 22136423 DOI: 10.1111/j.1349-7006.2011.02175.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
428 Torkamani A, Andersen KG, Steinhubl SR, Topol EJ. High-Definition Medicine. Cell 2017;170:828-43. [PMID: 28841416 DOI: 10.1016/j.cell.2017.08.007] [Cited by in Crossref: 105] [Cited by in F6Publishing: 86] [Article Influence: 21.0] [Reference Citation Analysis]
429 Ingold B, Schraml P, Heppner FL, Moch H. Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS One 2009;4:e4775. [PMID: 19274096 DOI: 10.1371/journal.pone.0004775] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
430 Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 2011;17:286-95. [PMID: 22005689 DOI: 10.1177/159101991101700302] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
431 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 2017;31:487-500.e8. [PMID: 28366679 DOI: 10.1016/j.ccell.2017.02.018] [Cited by in Crossref: 150] [Cited by in F6Publishing: 147] [Article Influence: 30.0] [Reference Citation Analysis]
432 Patel KS, Yao J, Raymond C, Yong W, Everson R, Liau LM, Nathanson D, Kornblum H, Wang C, Oughourlian T, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. Sci Rep 2020;10:14819. [PMID: 32908231 DOI: 10.1038/s41598-020-71799-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
433 Rizzo D, Ruggiero A, Martini M, Rizzo V, Maurizi P, Riccardi R. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. Biomed Res Int 2015;2015:215135. [PMID: 26448930 DOI: 10.1155/2015/215135] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
434 Paul Y, Mondal B, Patil V, Somasundaram K. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Clin Epigenetics 2017;9:32. [PMID: 28392842 DOI: 10.1186/s13148-017-0331-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
435 Mareike M, Franziska SB, Julia E, Daniel H, Michael S, Jörg F, Marion R. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients? J Neurooncol 2021;153:537-45. [PMID: 34185258 DOI: 10.1007/s11060-021-03794-8] [Reference Citation Analysis]
436 Kirby AJ, Finnerty GT. New strategies for managing adult gliomas. J Neurol 2021;268:3666-74. [PMID: 32542524 DOI: 10.1007/s00415-020-09884-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
437 Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15:338-345. [PMID: 19118063 DOI: 10.1158/1078-0432.ccr-08-1476] [Cited by in Crossref: 252] [Cited by in F6Publishing: 91] [Article Influence: 19.4] [Reference Citation Analysis]
438 Urbschat S, Sippl C, Engelhardt J, Kammers K, Oertel J, Ketter R. Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy. Mol Cytogenet 2017;10:16. [PMID: 28484518 DOI: 10.1186/s13039-017-0317-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
439 Jalal S, Earley JN, Turchi JJ. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res 2011;17:6973-84. [PMID: 21908578 DOI: 10.1158/1078-0432.CCR-11-0761] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
440 Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer 2010;103:1588-96. [PMID: 20978505 DOI: 10.1038/sj.bjc.6605946] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
441 Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death Dis 2014;5:e1223. [PMID: 24810059 DOI: 10.1038/cddis.2014.188] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
442 Awah CU, Winter J, Mazdoom CM, Ogunwobi OO. NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. Cancer Biol Ther 2021;:1-11. [PMID: 34705606 DOI: 10.1080/15384047.2021.1990631] [Reference Citation Analysis]
443 Collins VP, Ichimura K, Di Y, Pearson D, Chan R, Thompson LC, Gabe R, Brada M, Stenning SP; BR12 Collaborators. Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. Acta Neuropathol Commun 2014;2:68. [PMID: 24952577 DOI: 10.1186/2051-5960-2-68] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
444 Smith RP, Lam ET, Markova S, Yee SW, Ahituv N. Pharmacogene regulatory elements: from discovery to applications. Genome Med 2012;4:45. [PMID: 22630332 DOI: 10.1186/gm344] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
445 Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012;13:679-692. [PMID: 22945394 DOI: 10.1038/nrg3270] [Cited by in Crossref: 529] [Cited by in F6Publishing: 462] [Article Influence: 52.9] [Reference Citation Analysis]
446 Li Y, Hou M, Lu G, Ciccone N, Wang X, Zhang H. The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials. PLoS One 2016;11:e0168264. [PMID: 28005980 DOI: 10.1371/journal.pone.0168264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
447 De Carlo E, Gerratana L, De Maglio G, Buoro V, Cortiula F, Gurrieri L, Isola M, Fasola G, Puglisi F, Pizzolitto S, Rizzato S. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. J Neurooncol 2018;140:559-68. [PMID: 30132165 DOI: 10.1007/s11060-018-2981-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
448 Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA. Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomark Res 2013;1:29. [PMID: 24252135 DOI: 10.1186/2050-7771-1-29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
449 Li S, Shen L. The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients. Eur Arch Otorhinolaryngol 2021;278:3027-35. [PMID: 33386968 DOI: 10.1007/s00405-020-06477-8] [Reference Citation Analysis]
450 Rahman MA, Brekke J, Arnesen V, Hannisdal MH, Navarro AG, Waha A, Herfindal L, Rygh CB, Bratland E, Brandal P, Haasz J, Oltedal L, Miletic H, Lundervold A, Lie SA, Goplen D, Chekenya M. Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. Immun Inflamm Dis 2020;8:342-59. [PMID: 32578964 DOI: 10.1002/iid3.315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
451 Montano N, Cenci T, Martini M, D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, De Maria R, Larocca LM, Pallini R. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia 2011;13:1113-21. [PMID: 22241957 DOI: 10.1593/neo.111338] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 7.9] [Reference Citation Analysis]
452 Liu ZQ, Ren JJ, Zhao JL, Zang J, Long QF, Du JJ, Jia XT, Gu NB, Di ZL, Qian YH, Li SZ. MicroRNA-144 represses gliomas progression and elevates susceptibility to Temozolomide by targeting CAV2 and FGF7. Sci Rep 2020;10:4155. [PMID: 32139705 DOI: 10.1038/s41598-020-60218-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
453 Silvani A, Gaviani P, Lamperti EA, Eoli M, Falcone C, Dimeco F, Milanesi IM, Erbetta A, Boiardi A, Fariselli L, Salmaggi A. Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J Neurooncol 2009;94:57-62. [PMID: 19212704 DOI: 10.1007/s11060-009-9800-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
454 Cardona AF, Rojas L, Wills B, Behaine J, Jiménez E, Hakim F, Useche N, Bermúdez S, Arrieta O, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, González D, Rodríguez J, Ortiz LD, Cifuentes H, Balaña C. Genotyping low-grade gliomas among Hispanics. Neurooncol Pract 2016;3:164-72. [PMID: 31386063 DOI: 10.1093/nop/npv061] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
455 Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S. Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting. Protein Cell 2010;1:638-55. [PMID: 21203936 DOI: 10.1007/s13238-010-0078-y] [Cited by in Crossref: 141] [Cited by in F6Publishing: 134] [Article Influence: 11.8] [Reference Citation Analysis]
456 Conde-Moreno AJ, García-Gómez R, Albert-Antequera M, Almendros-Blanco P, De Las Peñas-Bataller R, González-Vidal V, López-Torrecilla JL, Ferrer-Albiach C. Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas. Rep Pract Oncol Radiother 2015;20:231-8. [PMID: 25949228 DOI: 10.1016/j.rpor.2015.01.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
457 Tezcan Y, Koc M. 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors. Radiol Oncol 2011;45:213-9. [PMID: 22933959 DOI: 10.2478/v10019-011-0019-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
458 Kim HY, Lee BI, Jeon JH, Kim DK, Kang SG, Shim JK, Kim SY, Kang SW, Jang H. Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres. Biomolecules 2019;9:E595. [PMID: 31658771 DOI: 10.3390/biom9100595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
459 Gatson NN, Chiocca EA, Kaur B. Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett 2012;527:62-70. [PMID: 22906922 DOI: 10.1016/j.neulet.2012.08.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
460 Weathers SP, Gilbert MR. Advances in treating glioblastoma. F1000Prime Rep 2014;6:46. [PMID: 24991423 DOI: 10.12703/P6-46] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
461 Nguyen N, Redfield J, Ballo M, Michael M, Sorenson J, Dibaba D, Wan J, Ramos GD, Pandey M. Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma. CNS Oncol 2021;10:CNS74. [PMID: 34486380 DOI: 10.2217/cns-2021-0002] [Reference Citation Analysis]
462 Wee CW, Sung W, Kang HC, Cho KH, Han TJ, Jeong BK, Jeong JU, Kim H, Kim IA, Kim JH, Kim SH, Kim S, Lee DS, Lee MY, Lim DH, Park HL, Suh CO, Yoon SM, Kim IH. Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology Group. Radiat Oncol 2015;10:137. [PMID: 26134973 DOI: 10.1186/s13014-015-0439-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
463 Lim YC, Ensbey KS, Offenhäuser C, D'souza RCJ, Cullen JK, Stringer BW, Quek H, Bruce ZC, Kijas A, Cianfanelli V, Mahboubi B, Smith F, Jeffree RL, Wiesmüeller L, Wiegmans AP, Bain A, Lombard FJ, Roberts TL, Khanna KK, Lavin MF, Kim B, Hamerlik P, Johns TG, Coster MJ, Boyd AW, Day BW. Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore. Neuro Oncol 2020;22:216-28. [PMID: 31504812 DOI: 10.1093/neuonc/noz159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
464 Laack NN, Sarkaria JN, Buckner JC. Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma? Semin Radiat Oncol 2015;25:197-202. [PMID: 26050590 DOI: 10.1016/j.semradonc.2015.02.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
465 Malta TM, de Souza CF, Sabedot TS, Silva TC, Mosella MS, Kalkanis SN, Snyder J, Castro AVB, Noushmehr H. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol. 2018;20:608-620. [PMID: 29036500 DOI: 10.1093/neuonc/nox183] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 21.3] [Reference Citation Analysis]
466 Mazurek M, Litak J, Kamieniak P, Osuchowska I, Maciejewski R, Roliński J, Grajkowska W, Grochowski C. Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme. Int J Mol Sci 2020;21:E1507. [PMID: 32098401 DOI: 10.3390/ijms21041507] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
467 Kewitz-Hempel S, Kurch L, Cepelova M, Volkmer I, Sauerbrey A, Conrad E, Knirsch S, Pöpperl G, Steinbach D, Beer AJ, Kramm CM, Sahlmann CO, Erdlenbruch B, Reinbold WD, Odparlik A, Sabri O, Kluge R, Staege MS. Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL). Mol Imaging Biol 2019;21:1182-91. [PMID: 30945122 DOI: 10.1007/s11307-019-01350-5] [Reference Citation Analysis]
468 Brell M, Ibáñez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer 2011;11:35. [PMID: 21269507 DOI: 10.1186/1471-2407-11-35] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
469 Wach J, Hamed M, Schuss P, Güresir E, Herrlinger U, Vatter H, Schneider M. Impact of initial midline shift in glioblastoma on survival. Neurosurg Rev 2021;44:1401-9. [PMID: 32494988 DOI: 10.1007/s10143-020-01328-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
470 Kim JH. Prognostic and predictive markers in glioblastoma and ALK overexpression. J Pathol Transl Med 2021;55:236-7. [PMID: 34015889 DOI: 10.4132/jptm.2021.04.29] [Reference Citation Analysis]
471 Zhang C, Du J, Xu W, Huang H, Gao L. The Value of Tumor Treating Fields in Glioblastoma. J Korean Neurosurg Soc 2020;63:681-8. [PMID: 32380584 DOI: 10.3340/jkns.2019.0224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
472 Li L, Huang Y, Gao Y, Shi T, Xu Y, Li H, Hyytiäinen M, Keski-Oja J, Jiang Q, Hu Y, Du Z. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence. BMC Cancer 2018;18:1215. [PMID: 30514230 DOI: 10.1186/s12885-018-5056-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
473 Arbab AS, Jain M, Achyut BR. p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment. Biochem Physiol 2016;5:e153. [PMID: 27917327 DOI: 10.4172/2168-9652.1000e153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
474 Castells X, Acebes JJ, Majós C, Boluda S, Julià-Sapé M, Candiota AP, Ariño J, Barceló A, Arús C. Robustness of equations that define molecular subtypes of glioblastoma tumors based on five transcripts measured by RT-PCR. OMICS 2015;19:41-51. [PMID: 25562199 DOI: 10.1089/omi.2014.0077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
475 Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, Clarke ID, Fuller GN, Kesari S, Dirks PB, McGlade CJ, Stanford WL, Aldape K, Mischel PS, Hawkins C, Guha A. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med 2011;208:689-702. [PMID: 21464220 DOI: 10.1084/jem.20102099] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
476 Vanan MI, Eisenstat DD. Management of high-grade gliomas in the pediatric patient: Past, present, and future. Neurooncol Pract. 2014;1:145-157. [PMID: 26034626 DOI: 10.1093/nop/npu022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
477 Yamaki T, Suenaga Y, Iuchi T, Alagu J, Takatori A, Itami M, Araki A, Ohira M, Inoue M, Kageyama H, Yokoi S, Saeki N, Nakagawara A. Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma. Sci Rep 2013;3:1160. [PMID: 23362460 DOI: 10.1038/srep01160] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
478 Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer O, Steinbrecher A, Hirschmann B, Brawanski A, Dietmaier C, Jauch-Worley T, Kölbl O, Pietsch T, Proescholdt M, Rümmele P, Muigg A, Stockhammer G, Hegi M, Bogdahn U, Hau P. RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. BMC Cancer 2009;9:308. [PMID: 19725960 DOI: 10.1186/1471-2407-9-308] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
479 Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn JC, Kretzschmar HA, Pöpperl G, Kreth FW. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 2011;13:307-16. [PMID: 21292686 DOI: 10.1093/neuonc/noq196] [Cited by in Crossref: 169] [Cited by in F6Publishing: 142] [Article Influence: 15.4] [Reference Citation Analysis]
480 Hirono S, Iwadate Y, Kambe M, Hiwasa T, Takiguchi M, Nakatani Y, Saeki N. Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. J Neurol Surg Rep 2015;76:e43-7. [PMID: 26251808 DOI: 10.1055/s-0034-1396657] [Reference Citation Analysis]
481 Gladson CL, Prayson RA, Liu WM. The pathobiology of glioma tumors. Annu Rev Pathol 2010;5:33-50. [PMID: 19737106 DOI: 10.1146/annurev-pathol-121808-102109] [Cited by in Crossref: 141] [Cited by in F6Publishing: 125] [Article Influence: 11.8] [Reference Citation Analysis]
482 Smrdel U, Popovic M, Zwitter M, Bostjancic E, Zupan A, Kovac V, Glavac D, Bokal D, Jerebic J. Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. Radiol Oncol 2016;50:394-401. [PMID: 27904447 DOI: 10.1515/raon-2015-0041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
483 Lv D, Yu SC, Ping YF, Wu H, Zhao X, Zhang H, Cui Y, Chen B, Zhang X, Dai J, Bian XW, Yao XH. A three-dimensional collagen scaffold cell culture system for screening anti-glioma therapeutics. Oncotarget. 2016;7:56904-56914. [PMID: 27486877 DOI: 10.18632/oncotarget.10885] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
484 Theeler BJ, Yung WK, Fuller GN, De Groot JF. Moving toward molecular classification of diffuse gliomas in adults. Neurology 2012;79:1917-26. [PMID: 23109653 DOI: 10.1212/WNL.0b013e318271f7cb] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
485 Hwang K, Lee JH, Kim SH, Go KO, Ji SY, Han JH, Kim CY. The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model. In Vivo 2021;35:2015-23. [PMID: 34182476 DOI: 10.21873/invivo.12470] [Reference Citation Analysis]
486 Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. JAMA Oncol 2017;3:784-92. [PMID: 28097324 DOI: 10.1001/jamaoncol.2016.6020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
487 Lassman AB, Roberts-Rapp L, Sokolova I, Song M, Pestova E, Kular R, Mullen C, Zha Z, Lu X, Gomez E, Bhathena A, Maag D, Kumthekar P, Gan HK, Scott AM, Guseva M, Holen KD, Ansell PJ, van den Bent MJ. Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.Clin Cancer Res. 2019;25:3259-3265. [PMID: 30796037 DOI: 10.1158/1078-0432.CCR-18-3034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
488 Tsai YL, Chang HH, Chen YC, Chang YC, Chen Y, Tsai WC. Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance. Biomedicines 2020;8:E339. [PMID: 32927743 DOI: 10.3390/biomedicines8090339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
489 Ellis HP, Greenslade M, Powell B, Spiteri I, Sottoriva A, Kurian KM. Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence. Front Oncol 2015;5:251. [PMID: 26636033 DOI: 10.3389/fonc.2015.00251] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
490 Hou BL, Wen S, Katsevman GA, Liu H, Urhie O, Turner RC, Carpenter J, Bhatia S. Magnetic Resonance Imaging Parameters and Their Impact on Survival of Patients with Glioblastoma: Tumor Perfusion Predicts Survival. World Neurosurg 2018:S1878-8750(18)32908-5. [PMID: 30593971 DOI: 10.1016/j.wneu.2018.12.085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
491 Sayegh ET, Kaur G, Bloch O, Parsa AT. Systematic review of protein biomarkers of invasive behavior in glioblastoma. Mol Neurobiol 2014;49:1212-44. [PMID: 24271659 DOI: 10.1007/s12035-013-8593-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
492 Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol 2015;8:16. [PMID: 25886184 DOI: 10.1186/s13045-015-0113-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
493 Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009;11:747-56. [PMID: 19221171 DOI: 10.1215/15228517-2009-012] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
494 Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro Oncol 2014;16:1630-8. [PMID: 25028501 DOI: 10.1093/neuonc/nou138] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
495 Agnihotri S, Burrell K, Buczkowicz P, Remke M, Golbourn B, Chornenkyy Y, Gajadhar A, Fernandez NA, Clarke ID, Barszczyk MS, Pajovic S, Ternamian C, Head R, Sabha N, Sobol RW, Taylor MD, Rutka JT, Jones C, Dirks PB, Zadeh G, Hawkins C. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov 2014;4:1198-213. [PMID: 25100205 DOI: 10.1158/2159-8290.CD-14-0157] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
496 Martin S, Janouskova H, Dontenwill M. Integrins and p53 pathways in glioblastoma resistance to temozolomide. Front Oncol 2012;2:157. [PMID: 23120745 DOI: 10.3389/fonc.2012.00157] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
497 Abe H, Natsumeda M, Kanemaru Y, Watanabe J, Tsukamoto Y, Okada M, Yoshimura J, Oishi M, Fujii Y. MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. Neurol Med Chir (Tokyo) 2018;58:290-5. [PMID: 29848907 DOI: 10.2176/nmc.ra.2018-0044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
498 Daniel P, Filiz G, Brown DV, Hollande F, Gonzales M, D'Abaco G, Papalexis N, Phillips WA, Malaterre J, Ramsay RG, Mantamadiotis T. Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation. Oncogenesis 2014;3:e108. [PMID: 24979279 DOI: 10.1038/oncsis.2014.21] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
499 Nagpal G, Sharma M, Kumar S, Chaudhary K, Gupta S, Gautam A, Raghava GP. PCMdb: pancreatic cancer methylation database. Sci Rep. 2014;4:4197. [PMID: 24569397 DOI: 10.1038/srep04197] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
500 Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382-7. [PMID: 21252041 DOI: 10.3174/ajnr.A2286] [Cited by in Crossref: 138] [Cited by in F6Publishing: 67] [Article Influence: 12.5] [Reference Citation Analysis]
501 Kaina B, Margison GP, Christmann M. Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 2010;67:3663-81. [PMID: 20717836 DOI: 10.1007/s00018-010-0491-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 7.9] [Reference Citation Analysis]
502 Urbańczyk H, Strączyńska-Niemiec A, Głowacki G, Lange D, Miszczyk L. Case presentation - A five-year survival of the patient with glioblastoma brain tumor. Rep Pract Oncol Radiother 2014;19:347-51. [PMID: 25184061 DOI: 10.1016/j.rpor.2014.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
503 Shafi A, Nguyen T, Peyvandipour A, Nguyen H, Draghici S. A Multi-Cohort and Multi-Omics Meta-Analysis Framework to Identify Network-Based Gene Signatures. Front Genet 2019;10:159. [PMID: 30941158 DOI: 10.3389/fgene.2019.00159] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
504 Carmo A, Carvalheiro H, Crespo I, Nunes I, Lopes MC. Effect of temozolomide on the U-118 glioma cell line. Oncol Lett 2011;2:1165-70. [PMID: 22848283 DOI: 10.3892/ol.2011.406] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
505 Cao JY, Guo Q, Guan GF, Zhu C, Zou CY, Zhang LY, Cheng W, Wang GL, Cheng P, Wu AH, Li GY. Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma. Aging (Albany NY) 2020;12:1656-84. [PMID: 32003759 DOI: 10.18632/aging.102706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
506 Zhou J, Reddy MV, Wilson BKJ, Blair DA, Taha A, Frampton CM, Eiholzer RA, Gan PYC, Ziad F, Thotathil Z, Kirs S, Hung NA, Royds JA, Slatter TL. MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication. AJNR Am J Neuroradiol 2018;39:252-9. [PMID: 29191871 DOI: 10.3174/ajnr.A5441] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
507 Paccapelo A, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Santoni M, Bonizzoni E, Perrone T, Scoccianti S. A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. J Transl Med 2012;10:90. [PMID: 22583678 DOI: 10.1186/1479-5876-10-90] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
508 Casati G, Giunti L, Iorio AL, Marturano A, Galli L, Sardi I. Hippo Pathway in Regulating Drug Resistance of Glioblastoma. IJMS 2021;22:13431. [DOI: 10.3390/ijms222413431] [Reference Citation Analysis]
509 Nandi S, Lesniak MS. Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther 2009;9:737-47. [PMID: 19456208 DOI: 10.1517/14712590902988451] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
510 Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010;12:116-21. [PMID: 20150378 DOI: 10.1093/neuonc/nop020] [Cited by in Crossref: 210] [Cited by in F6Publishing: 195] [Article Influence: 16.2] [Reference Citation Analysis]
511 Stetson LC, Ostrom QT, Schlatzer D, Liao P, Devine K, Waite K, Couce ME, Harris PLR, Kerstetter-Fogle A, Berens ME, Sloan AE, Islam MM, Rajaratnam V, Mirza SP, Chance MR, Barnholtz-Sloan JS. Proteins inform survival-based differences in patients with glioblastoma. Neurooncol Adv 2020;2:vdaa039. [PMID: 32642694 DOI: 10.1093/noajnl/vdaa039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
512 Ji N, Zhang Y, Liu Y, Xie J, Wang Y, Hao S, Gao Z. Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial. JCI Insight 2018;3:99145. [PMID: 29769450 DOI: 10.1172/jci.insight.99145] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
513 Yurtsever A, Haydaroglu A, Biray Avci C, Gunduz C, Oktar N, Dalbasti T, Caglar HO, Attar R, Kitapcioglu G. Assessment of genetic markers and glioblastoma stem-like cells in activation of dendritic cells. Hum Cell 2013;26:105-13. [PMID: 23737374 DOI: 10.1007/s13577-013-0065-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
514 Li J, Di C, Mattox AK, Wu L, Adamson DC. The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med 2010;3:111-27. [PMID: 23226047 DOI: 10.2147/PGPM.S6852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
515 Gilbert MR. Advances in the treatment of primary brain tumors: dawn of a new era? Curr Oncol Rep 2006;8:45-9. [PMID: 16464402 DOI: 10.1007/s11912-006-0008-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
516 Yu W, Wu P, Wang F, Miao L, Han B, Jiang Z. Construction of Novel Methylation-Driven Gene Model and Investigation of PARVB Function in Glioblastoma. Front Oncol 2021;11:705547. [PMID: 34568031 DOI: 10.3389/fonc.2021.705547] [Reference Citation Analysis]
517 Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Pia Foschini M, Bartolini S, Pession A, Ermani M. Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist 2017;22:432-7. [PMID: 28275120 DOI: 10.1634/theoncologist.2016-0254] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
518 Wang X, Chen JX, Liu YH, You C, Mao Q. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. Neurol Sci 2013;34:1421-8. [PMID: 23224642 DOI: 10.1007/s10072-012-1257-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
519 Huang Z, Lu C, Li G, Li Z, Sun S, Zhang Y, Hou Z, Xie J. Prediction of Lower Grade Insular Glioma Molecular Pathology Using Diffusion Tensor Imaging Metric-Based Histogram Parameters. Front Oncol 2021;11:627202. [PMID: 33777772 DOI: 10.3389/fonc.2021.627202] [Reference Citation Analysis]
520 Komotar RJ, Otten ML, Moise G, Connolly ES Jr. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma-a critical review. Clin Med Oncol 2008;2:421-2. [PMID: 21892310 DOI: 10.4137/cmo.s390] [Cited by in Crossref: 8] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
521 Pojo M, Gonçalves CS, Xavier-Magalhães A, Oliveira AI, Gonçalves T, Correia S, Rodrigues AJ, Costa S, Pinto L, Pinto AA, Lopes JM, Reis RM, Rocha M, Sousa N, Costa BM. A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget 2015;6:7657-74. [PMID: 25762636 DOI: 10.18632/oncotarget.3150] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
522 Cousin D, Hummersone MG, Bradshaw TD, Zhang J, Moody CJ, Foreiter MB, Summers HS, Lewis W, Wheelhouse RT, Stevens MFG. Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position. Medchemcomm 2018;9:545-53. [PMID: 30108945 DOI: 10.1039/c7md00554g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
523 Sun S, Lee D, Lee NP, Pu JK, Wong ST, Lui WM, Fung CF, Leung GK. Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. J Neurooncol 2012;109:467-75. [PMID: 22763762 DOI: 10.1007/s11060-012-0923-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
524 Marzese DM, Hoon DS. Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn 2015;15:647-64. [PMID: 25797072 DOI: 10.1586/14737159.2015.1027194] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
525 Berger K, Turowski B, Felsberg J, Malzkorn B, Reifenberger G, Steiger HJ, Budach W, Haussmann J, Knipps J, Rapp M, Hänggi D, Sabel M, Mijderwijk HJ, Kamp MA. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. J Cancer Res Clin Oncol 2021;147:253-62. [PMID: 32748120 DOI: 10.1007/s00432-020-03334-3] [Reference Citation Analysis]
526 Kelley K, Knisely J, Symons M, Ruggieri R. Radioresistance of Brain Tumors. Cancers (Basel) 2016;8:E42. [PMID: 27043632 DOI: 10.3390/cancers8040042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
527 Brown CC, Havener TM, Medina MW, Auman JT, Mangravite LM, Krauss RM, McLeod HL, Motsinger-Reif AA. A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics 2012;22:796-802. [PMID: 23047291 DOI: 10.1097/FPC.0b013e3283589c50] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
528 Urbantat RM, Jelgersma C, Brandenburg S, Nieminen-Kelhä M, Kremenetskaia I, Zollfrank J, Mueller S, Rubarth K, Koch A, Vajkoczy P, Acker G. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy. Int J Mol Sci 2021;22:11180. [PMID: 34681839 DOI: 10.3390/ijms222011180] [Reference Citation Analysis]
529 Johnson DR, Fogh SE, Giannini C, Kaufmann TJ, Raghunathan A, Theodosopoulos PV, Clarke JL. Case-Based Review: newly diagnosed glioblastoma. Neurooncol Pract 2015;2:106-21. [PMID: 31386093 DOI: 10.1093/nop/npv020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
530 Lin AL, Sum MW, DeAngelis LM. Is there a role for early chemotherapy in the management of pituitary adenomas? Neuro Oncol 2016;18:1350-6. [PMID: 27106409 DOI: 10.1093/neuonc/now059] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
531 Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol 2007;82:133-9. [PMID: 17048097 DOI: 10.1007/s11060-006-9264-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
532 Zadran S, Remacle F, Levine R. Surprisal analysis of Glioblastoma Multiform (GBM) microRNA dynamics unveils tumor specific phenotype. PLoS One 2014;9:e108171. [PMID: 25265448 DOI: 10.1371/journal.pone.0108171] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
533 Ishida CT, Karpel-Massler G, Siegelin MD. BET-inhibitors as sensitizers for BH3-mimetics. Aging (Albany NY) 2017;9:1475-6. [PMID: 28657545 DOI: 10.18632/aging.101259] [Reference Citation Analysis]
534 Paech D, Windschuh J, Oberhollenzer J, Dreher C, Sahm F, Meissner JE, Goerke S, Schuenke P, Zaiss M, Regnery S, Bickelhaupt S, Bäumer P, Bendszus M, Wick W, Unterberg A, Bachert P, Ladd ME, Schlemmer HP, Radbruch A. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol 2018;20:1661-71. [PMID: 29733378 DOI: 10.1093/neuonc/noy073] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 17.7] [Reference Citation Analysis]
535 Wang Y, Chen X, Zhang Z, Li S, Chen B, Wu C, Wang L, Zhang X, Wang J, Chen L, Jiang T. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Neurosurg Rev 2014;37:73-8. [PMID: 23912878 DOI: 10.1007/s10143-013-0490-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
536 Kim SS, Rait A, Kim E, Pirollo KF, Chang EH. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine 2015;11:301-11. [PMID: 25240597 DOI: 10.1016/j.nano.2014.09.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
537 Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys 2018;100:1195-203. [PMID: 29722661 DOI: 10.1016/j.ijrobp.2018.01.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
538 Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA. Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019;7:E69. [PMID: 31505812 DOI: 10.3390/biomedicines7030069] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 16.7] [Reference Citation Analysis]
539 Wu S, Qiao Q, Li G. A Radiosensitivity Gene Signature and XPO1 Predict Clinical Outcomes for Glioma Patients. Front Oncol 2020;10:871. [PMID: 32612949 DOI: 10.3389/fonc.2020.00871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
540 Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011;13:1244-1251. [PMID: 21831900 DOI: 10.1093/neuonc/nor117] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
541 Carter TC, Medina-Flores R, Lawler BE. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. Biomed Res Int 2018;2018:6204676. [PMID: 30687753 DOI: 10.1155/2018/6204676] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
542 Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 2017;8:79298-304. [PMID: 29108308 DOI: 10.18632/oncotarget.17837] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
543 Egaña L, Auzmendi-Iriarte J, Andermatten J, Villanua J, Ruiz I, Elua-Pinin A, Aldaz P, Querejeta A, Sarasqueta C, Zubia F, Matheu A, Samprón N. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. Sci Rep 2020;10:18445. [PMID: 33116181 DOI: 10.1038/s41598-020-75477-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
544 Ma J, Setton J, Lee NY, Riaz N, Powell SN. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun 2018;9:3292. [PMID: 30120226 DOI: 10.1038/s41467-018-05228-y] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 20.8] [Reference Citation Analysis]
545 Lee DH, Ryu HW, Won HR, Kwon SH. Advances in epigenetic glioblastoma therapy. Oncotarget 2017;8:18577-89. [PMID: 28099914 DOI: 10.18632/oncotarget.14612] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
546 Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 2014;14:17. [PMID: 24418474 DOI: 10.1186/1471-2407-14-17] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 8.8] [Reference Citation Analysis]
547 Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol 2011;13:736-47. [PMID: 21642372 DOI: 10.1093/neuonc/nor036] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
548 Doolittle ND, Peereboom DM, Christoforidis GA, Hall WA, Palmieri D, Brock PR, Campbell KC, Dickey DT, Muldoon LL, O'Neill BP, Peterson DR, Pollock B, Soussain C, Smith Q, Tyson RM, Neuwelt EA. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. J Neurooncol 2007;81:81-91. [PMID: 16858513 DOI: 10.1007/s11060-006-9209-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
549 Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med 2019;11:eaaw5680. [PMID: 31413142 DOI: 10.1126/scitranslmed.aaw5680] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 31.0] [Reference Citation Analysis]
550 Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol 2011;13:974-82. [PMID: 21764822 DOI: 10.1093/neuonc/nor077] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 8.6] [Reference Citation Analysis]
551 Wang Y, Long P, Wang Y, Ma W. NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma. Front Oncol 2020;10:593578. [PMID: 33330081 DOI: 10.3389/fonc.2020.593578] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
552 Feldheim J, Kessler AF, Monoranu CM, Ernestus RI, Löhr M, Hagemann C. Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review. Cancers (Basel) 2019;11:E1837. [PMID: 31766430 DOI: 10.3390/cancers11121837] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
553 Katsoulakis E, Beal K, Yamada Y. Image guidance in malignant gliomas: a focused strategy. CNS Oncol 2012;1:131-6. [PMID: 25057863 DOI: 10.2217/cns.12.21] [Reference Citation Analysis]
554 Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29:142-8. [PMID: 21135282 DOI: 10.1200/JCO.2010.30.2729] [Cited by in Crossref: 320] [Cited by in F6Publishing: 191] [Article Influence: 26.7] [Reference Citation Analysis]
555 Li L, Hu Y, Ylivinkka I, Li H, Chen P, Keski-Oja J, Hyytiäinen M. NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence. PLoS One 2013;8:e80363. [PMID: 24265816 DOI: 10.1371/journal.pone.0080363] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
556 Guo Q, Xiao X, Zhang J. MYD88 Is a Potential Prognostic Gene and Immune Signature of Tumor Microenvironment for Gliomas. Front Oncol 2021;11:654388. [PMID: 33898320 DOI: 10.3389/fonc.2021.654388] [Reference Citation Analysis]
557 Czapski B, Baluszek S, Herold-Mende C, Kaminska B. Clinical and immunological correlates of long term survival in glioblastoma. Contemp Oncol (Pozn) 2018;22:81-5. [PMID: 29628799 DOI: 10.5114/wo.2018.73893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
558 Umans RA, Ten Kate M, Pollock C, Sontheimer H. Fishing for Contact: Modeling Perivascular Glioma Invasion in the Zebrafish Brain. ACS Pharmacol Transl Sci 2021;4:1295-305. [PMID: 34423267 DOI: 10.1021/acsptsci.0c00129] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
559 Kraboth Z, Kalman B. Longitudinal Characteristics of Glioblastoma in Genome-Wide Studies. Pathol Oncol Res 2020;26:2035-47. [PMID: 31376079 DOI: 10.1007/s12253-019-00705-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
560 Seliger C, Schaertl J, Gerken M, Luber C, Proescholdt M, Riemenschneider MJ, Leitzmann MF, Hau P, Klinkhammer-Schalke M. Use of statins or NSAIDs and survival of patients with high-grade glioma. PLoS One 2018;13:e0207858. [PMID: 30507932 DOI: 10.1371/journal.pone.0207858] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
561 Lasri A, Juric V, Verreault M, Bielle F, Idbaih A, Kel A, Murphy B, Sturrock M. Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics. R Soc Open Sci 2020;7:191243. [PMID: 32874597 DOI: 10.1098/rsos.191243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
562 Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst 2012;104:1458-69. [PMID: 22945948 DOI: 10.1093/jnci/djs357] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
563 Henriksen M, Johnsen KB, Andersen HH, Pilgaard L, Duroux M. MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview. Mol Neurobiol 2014;50:896-913. [PMID: 24619503 DOI: 10.1007/s12035-014-8668-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
564 Coleman N, Ameratunga M, Lopez J. Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. Clin Med Insights Oncol 2018;12:1179554918759079. [PMID: 29511362 DOI: 10.1177/1179554918759079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
565 Moreau A, Febvey O, Mognetti T, Frappaz D, Kryza D. Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma. Front Oncol 2019;9:1134. [PMID: 31737567 DOI: 10.3389/fonc.2019.01134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
566 Nagane M, Kobayashi K, Tanaka M, Tsuchiya K, Shishido-Hara Y, Shimizu S, Shiokawa Y. Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. Int J Clin Oncol 2014;19:16-23. [PMID: 23354833 DOI: 10.1007/s10147-013-0517-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
567 Sanai N, Berger MS. Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics. 2009;6:478-486. [PMID: 19560738 DOI: 10.1016/j.nurt.2009.04.005] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
568 Hegi ME, Stupp R. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma? Neuro Oncol 2015;17:1425-7. [PMID: 26374690 DOI: 10.1093/neuonc/nov198] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 7.4] [Reference Citation Analysis]
569 Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F, Bendszus M, Unterberg A, Platten M, Wick W, Wick A. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. J Neurooncol 2014;117:85-92. [PMID: 24458956 DOI: 10.1007/s11060-013-1356-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
570 Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, Ryu S, Werner-Wasik M, Bahary JP, Liu J, Chakravarti A, Mehta M. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys 2015;91:497-504. [PMID: 25680596 DOI: 10.1016/j.ijrobp.2014.11.012] [Cited by in Crossref: 106] [Cited by in F6Publishing: 72] [Article Influence: 15.1] [Reference Citation Analysis]
571 Arvold ND, Cefalu M, Wang Y, Zigler C, Schrag D, Dominici F. Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. J Neurooncol 2017;131:301-11. [PMID: 27770280 DOI: 10.1007/s11060-016-2294-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
572 Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathol 2018;135:601-15. [PMID: 29368212 DOI: 10.1007/s00401-018-1810-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
573 Zhang K, Wang XQ, Zhou B, Zhang L. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer 2013;12:449-58. [PMID: 23397067 DOI: 10.1007/s10689-013-9607-1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
574 Fujihara T, Mizobuchi Y, Nakajima K, Kageji T, Matsuzaki K, Kitazato KT, Otsuka R, Hara K, Mure H, Okazaki T, Kuwayama K, Nagahiro S, Takagi Y. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model. J Neurooncol 2018;139:323-32. [PMID: 29779087 DOI: 10.1007/s11060-018-2894-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
575 Patel CB, Beinat C, Xie Y, Chang E, Gambhir SS. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. Neoplasia 2021;23:58-67. [PMID: 33221711 DOI: 10.1016/j.neo.2020.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
576 Cha YJ, Kim SH, Kim NR. Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea. J Pathol Transl Med 2020;54:165-70. [PMID: 32070090 DOI: 10.4132/jptm.2020.02.04] [Reference Citation Analysis]
577 Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer MC, Wakimoto H, Barazas M, Tannous M, Chi AS, Noske DP, Wesseling P, Wurdinger T, Batchelor TT, Tannous BA. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol 2018;20:642-54. [PMID: 29099956 DOI: 10.1093/neuonc/nox198] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
578 Liu Y, Song C, Ladas I, Fitarelli-Kiehl M, Makrigiorgos GM. Methylation-sensitive enrichment of minor DNA alleles using a double-strand DNA-specific nuclease. Nucleic Acids Res 2017;45:e39. [PMID: 27903892 DOI: 10.1093/nar/gkw1166] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
579 Ryu JY, Min KL, Chang MJ. Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study. PLoS One 2019;14:e0225599. [PMID: 31790459 DOI: 10.1371/journal.pone.0225599] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
580 Sohn B, An C, Kim D, Ahn SS, Han K, Kim SH, Kang SG, Chang JH, Lee SK. Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant. J Neurooncol 2021. [PMID: 34648115 DOI: 10.1007/s11060-021-03870-z] [Reference Citation Analysis]
581 Kronfol MM, Dozmorov MG, Huang R, Slattum PW, McClay JL. The role of epigenomics in personalized medicine. Expert Rev Precis Med Drug Dev 2017;2:33-45. [PMID: 29276780 DOI: 10.1080/23808993.2017.1284557] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
582 Tóth C, Sükösd F, Valicsek E, Herpel E, Schirmacher P, Tiszlavicz L. Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer. Oncol Lett 2018;15:3586-93. [PMID: 29467879 DOI: 10.3892/ol.2018.7756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
583 Comba A, Faisal SM, Varela ML, Hollon T, Al-Holou WN, Umemura Y, Nunez FJ, Motsch S, Castro MG, Lowenstein PR. Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. Front Oncol 2021;11:703764. [PMID: 34422657 DOI: 10.3389/fonc.2021.703764] [Reference Citation Analysis]
584 Lin AL, Donoghue MTA, Wardlaw SL, Yang TJ, Bodei L, Tabar V, Geer EB. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. J Clin Endocrinol Metab 2020;105:dgaa649. [PMID: 32930787 DOI: 10.1210/clinem/dgaa649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
585 Lu Y, Liu Y, Pang Y, Pacak K, Yang C. Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. Pharmacol Ther 2018;188:168-75. [PMID: 29621593 DOI: 10.1016/j.pharmthera.2018.03.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
586 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol 2009;95:393-400. [PMID: 19533023 DOI: 10.1007/s11060-009-9937-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
587 Wehmas LC, Tanguay RL, Punnoose A, Greenwood JA. Developing a Novel Embryo-Larval Zebrafish Xenograft Assay to Prioritize Human Glioblastoma Therapeutics. Zebrafish 2016;13:317-29. [PMID: 27158859 DOI: 10.1089/zeb.2015.1170] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
588 Franzese O, Torino F, Giannetti E, Cioccoloni G, Aquino A, Faraoni I, Fuggetta MP, De Vecchis L, Giuliani A, Kaina B, Bonmassar E. Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment? Int J Mol Sci 2021;22:10672. [PMID: 34639014 DOI: 10.3390/ijms221910672] [Reference Citation Analysis]
589 Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, Suh JH, Vogelbaum MA, Peereboom DM, Zouaoui S, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Taillandier L, Abrey LE, DeAngelis LM, Shih JH, Iwamoto FM. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 2012;118:5595-600. [PMID: 22517216 DOI: 10.1002/cncr.27570] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
590 Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yang K, Kim Y, Minhas S, Rich JN, Hjelmeland AB. Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des 2011;17:2386-401. [PMID: 21827414 DOI: 10.2174/138161211797249260] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
591 Muracciole X, El-Amine W, Tabouret E, Boucekine M, Barlier A, Petrirena G, Harivony T, Solignac L, Chinot OL, Macagno N, Figarella-Branger D, Padovani L. Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population. Front Oncol. 2018;8:426. [PMID: 30338243 DOI: 10.3389/fonc.2018.00426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
592 Pollack IF. Ataxia resulting from posterior fossa tumors of childhood and other mass lesions. Ataxic Disorders. Elsevier; 2012. pp. 161-73. [DOI: 10.1016/b978-0-444-51892-7.00009-7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
593 Chen YH, Hueng DY, Tsai WC. Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas. Int J Mol Sci 2018;19:E3353. [PMID: 30373180 DOI: 10.3390/ijms19113353] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
594 Mazor T, Pankov A, Song JS, Costello JF. Intratumoral Heterogeneity of the Epigenome. Cancer Cell 2016;29:440-51. [PMID: 27070699 DOI: 10.1016/j.ccell.2016.03.009] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 19.3] [Reference Citation Analysis]
595 Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 2009;32:265-73; discussion 273. [PMID: 19214609 DOI: 10.1007/s10143-009-0189-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
596 Baraibar I, Mirallas O, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:6311. [PMID: 34944931 DOI: 10.3390/cancers13246311] [Reference Citation Analysis]
597 Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Moore PF, Avalos J, Young JD, Khan D. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One. 2010;5:e11074. [PMID: 20552015 DOI: 10.1371/journal.pone.0011074] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
598 Chaichana KL, Jusue-Torres I, Lemos AM, Gokaslan A, Cabrera-Aldana EE, Ashary A, Olivi A, Quinones-Hinojosa A. The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors? J Neurooncol 2014;120:625-34. [PMID: 25193022 DOI: 10.1007/s11060-014-1597-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
599 Tendulkar RD, Pai Panandiker AS, Wu S, Kun LE, Broniscer A, Sanford RA, Merchant TE. Irradiation of pediatric high-grade spinal cord tumors. Int J Radiat Oncol Biol Phys 2010;78:1451-6. [PMID: 20346593 DOI: 10.1016/j.ijrobp.2009.09.071] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
600 Ambady P, Wu YJ, Walker JM, Kersch C, Pagel MA, Woltjer RL, Fu R, Muldoon LL, Neuwelt EA. Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors. Cancer Gene Ther 2017;24:348-57. [PMID: 28752860 DOI: 10.1038/cgt.2017.27] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
601 Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, Ray-Chaudhuri A, Chakravarti A, Grecula J, Newton H, Harris KS, Grossman RG, Trask TW, Baskin DS, Monterroso C, Manzanera AG, Aguilar-Cordova E, New PZ. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol 2011;29:3611-9. [PMID: 21844505 DOI: 10.1200/JCO.2011.35.5222] [Cited by in Crossref: 92] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
602 Hachem LD, Mansouri A, Juraschka K, Taslimi S, Pirouzmand F, Zadeh G. Citation classics in neuro-oncology: assessment of historical trends and scientific progress. Neuro Oncol 2017;19:1158-72. [PMID: 28531344 DOI: 10.1093/neuonc/nox053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
603 Shirai K, Siedow MR, Chakravarti A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J Oncol 2012;2012:193436. [PMID: 21804824 DOI: 10.1155/2012/193436] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
604 Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL, Megahed H, Garami M, Hauser P, Dembowska-Baginska B, Perek D, Northcott PA, Taylor MD, Taylor RE, Ellison DW, Bailey S, Clifford SC. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 2013;125:359-71. [PMID: 23291781 DOI: 10.1007/s00401-012-1077-2] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 9.7] [Reference Citation Analysis]
605 Kim SK, Kim TM, Lee ST, Lee SH, Heo DS, Kim IH, Kim DG, Jung HW, Choi SH, Lee SH, Park CK. The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. J Clin Neurosci 2016;34:145-50. [PMID: 27475318 DOI: 10.1016/j.jocn.2016.06.014] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
606 Eibl RH, Schneemann M. Liquid Biopsy and Primary Brain Tumors. Cancers (Basel) 2021;13:5429. [PMID: 34771592 DOI: 10.3390/cancers13215429] [Reference Citation Analysis]
607 Alfardus H, McIntyre A, Smith S. MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma. Biomed Res Int 2017;2017:9157370. [PMID: 28804724 DOI: 10.1155/2017/9157370] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
608 Lanza M, Casili G, Campolo M, Paterniti I, Colarossi C, Mare M, Giuffrida R, Caffo M, Esposito E, Cuzzocrea S. Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas. Brain Sci 2021;11:466. [PMID: 33917013 DOI: 10.3390/brainsci11040466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
609 Tran A, Escovedo C, Migdall-Wilson J, Chou AP, Chen W, Cloughesy T, Nelson S, Lai A. In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays. Front Neurosci 2009;3:57. [PMID: 20582289 DOI: 10.3389/neuro.15.005.2009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
610 Lass U, Nümann A, von Eckardstein K, Kiwit J, Stockhammer F, Horaczek JA, Veelken J, Herold-Mende C, Jeuken J, von Deimling A, Mueller W. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLoS One 2012;7:e41298. [PMID: 22844452 DOI: 10.1371/journal.pone.0041298] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
611 Kesarwani P, Prabhu A, Kant S, Chinnaiyan P. Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma. Cancer Immunol Immunother 2019;68:1107-20. [PMID: 31119318 DOI: 10.1007/s00262-019-02347-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
612 Chen X, Tai L, Gao J, Qian J, Zhang M, Li B, Xie C, Lu L, Lu W, Lu W. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. J Control Release 2015;218:29-35. [PMID: 26428461 DOI: 10.1016/j.jconrel.2015.09.061] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
613 Gupta A, Omuro AM, Shah AD, Graber JJ, Shi W, Zhang Z, Young RJ. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology 2012;54:641-3. [PMID: 22006425 DOI: 10.1007/s00234-011-0970-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
614 Priesterbach-Ackley LP, Wesseling P, Snijders TJ, de Vos FYFL, de Leng WWJ. Molecular tools for the pathologic diagnosis of central nervous system tumors. Neurooncol Pract 2019;6:4-16. [PMID: 31386041 DOI: 10.1093/nop/npy041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
615 Alexander BM, Pinnell N, Wen PY, D’Andrea A. Targeting DNA repair and the cell cycle in glioblastoma. J Neurooncol. 2012;107:463-477. [PMID: 22113697 DOI: 10.1007/s11060-011-0765-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
616 Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462-477. [PMID: 24120142 DOI: 10.1016/j.cell.2013.09.034] [Cited by in Crossref: 2579] [Cited by in F6Publishing: 2318] [Article Influence: 286.6] [Reference Citation Analysis]
617 Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, VandenBerg SR, Lal A. An orthotopic skull base model of malignant meningioma. Brain Pathol 2008;18:172-9. [PMID: 18093250 DOI: 10.1111/j.1750-3639.2007.00109.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
618 Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010;10:753-68. [PMID: 21269250 DOI: 10.2174/187152010794728639] [Cited by in Crossref: 423] [Cited by in F6Publishing: 386] [Article Influence: 38.5] [Reference Citation Analysis]
619 Skiriute D, Vaitkiene P, Saferis V, Asmoniene V, Skauminas K, Deltuva VP, Tamasauskas A. MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. BMC Cancer 2012;12:218. [PMID: 22672670 DOI: 10.1186/1471-2407-12-218] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
620 Dong XT, Yang XJ, Wang HM, Wang W, Yu L, Zhang B, Yu SP, Ming HL. Expression and Distribution Characteristics of Human Ortholog of Mammalian Enabled (hMena) in Glioma. Chin J Cancer Res 2011;23:312-6. [PMID: 23359755 DOI: 10.1007/s11670-011-0312-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
621 Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J, Reifenberger G. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 2012;108:89-97. [PMID: 22307805 DOI: 10.1007/s11060-012-0798-3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 10.0] [Reference Citation Analysis]
622 Yoon SJ, Shim JK, Chang JH, Moon JH, Roh TH, Sung KS, Lee JH, Kim EH, Kim SH, Hong YK, Lee SJ, Huh YM, Kang SG. Tumor Mesenchymal Stem-Like Cell as a Prognostic Marker in Primary Glioblastoma. Stem Cells Int 2016;2016:6756983. [PMID: 26981133 DOI: 10.1155/2016/6756983] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
623 Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol 2011;13:1331-8. [PMID: 21896554 DOI: 10.1093/neuonc/nor130] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
624 Komori T. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. Lab Invest 2021. [PMID: 34504304 DOI: 10.1038/s41374-021-00667-6] [Reference Citation Analysis]
625 Huang L, Dai L, Xu W, Zhang S, Yan D, Shi X. Identification of expression quantitative trait loci of MTOR associated with the progression of glioma. Oncol Lett 2018;15:665-71. [PMID: 29387238 DOI: 10.3892/ol.2017.7319] [Reference Citation Analysis]
626 Dong X, Noorbakhsh A, Hirshman BR, Zhou T, Tang JA, Chang DC, Carter BS, Chen CC. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. Neurooncol Pract 2016;3:29-38. [PMID: 31579519 DOI: 10.1093/nop/npv016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
627 Kuester D, El-Rifai W, Peng D, Ruemmele P, Kroeckel I, Peters B, Moskaluk CA, Stolte M, Mönkemüller K, Meyer F, Schulz HU, Hartmann A, Roessner A, Schneider-Stock R. Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett 2009;275:117-26. [PMID: 19027227 DOI: 10.1016/j.canlet.2008.10.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
628 Genoud V, Migliorini D. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. Int J Mol Sci 2021;22:3493. [PMID: 33800593 DOI: 10.3390/ijms22073493] [Reference Citation Analysis]
629 Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther. 2009;8:2243-2254. [PMID: 19671736 DOI: 10.1158/1535-7163.MCT-09-0201] [Cited by in Crossref: 83] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
630 Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM, Pallini R, Traficante A, Spinsanti P, Ricci-Vitiani L, Arcella A, De Maria R, Nicoletti F, Battaglia G, Melchiorri D. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ 2013;20:396-407. [PMID: 23175182 DOI: 10.1038/cdd.2012.150] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
631 Woehrer A, Hainfellner JA. Molecular diagnostics: techniques and recommendations for 1p/19q assessment. CNS Oncol 2015;4:295-306. [PMID: 26545171 DOI: 10.2217/cns.15.28] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
632 Hassler M, Micksche M, Stockhammer G, Pichler J, Payer F, Abuja B, Deinsberger R, Marosi C. Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. Wien Klin Wochenschr 2006;118:230-8. [PMID: 16794761 DOI: 10.1007/s00508-006-0576-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
633 Hiddingh L, Raktoe RS, Jeuken J, Hulleman E, Noske DP, Kaspers GJ, Vandertop WP, Wesseling P, Wurdinger T. Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. Sci Rep 2014;4:5260. [PMID: 24919120 DOI: 10.1038/srep05260] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
634 Mazor T, Pankov A, Johnson BE, Hong C, Hamilton EG, Bell RJA, Smirnov IV, Reis GF, Phillips JJ, Barnes MJ, Idbaih A, Alentorn A, Kloezeman JJ, Lamfers MLM, Bollen AW, Taylor BS, Molinaro AM, Olshen AB, Chang SM, Song JS, Costello JF. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell 2015;28:307-17. [PMID: 26373278 DOI: 10.1016/j.ccell.2015.07.012] [Cited by in Crossref: 165] [Cited by in F6Publishing: 134] [Article Influence: 23.6] [Reference Citation Analysis]
635 Feng HB, Wang J, Jiang HR, Mei X, Zhao YY, Chen FR, Qu Y, Sai K, Guo CC, Yang QY, Zhang ZP, Chen ZP. β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1. Stem Cells Transl Med 2017;6:830-9. [PMID: 28297578 DOI: 10.5966/sctm.2016-0009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
636 Leelatian N, Sinnaeve J, Mistry AM, Barone SM, Brockman AA, Diggins KE, Greenplate AR, Weaver KD, Thompson RC, Chambless LB, Mobley BC, Ihrie RA, Irish JM. Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells. Elife 2020;9:e56879. [PMID: 32573435 DOI: 10.7554/eLife.56879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
637 Cowman S, Pizer B, Sée V. Downregulation of both mismatch repair and non-homologous end-joining pathways in hypoxic brain tumour cell lines. PeerJ 2021;9:e11275. [PMID: 33986995 DOI: 10.7717/peerj.11275] [Reference Citation Analysis]
638 Zhang Y, Liu Y, Liu H, Zhao Z, Wu F, Zeng F. Clinical and Biological Significances of a Methyltransferase-Related Signature in Diffuse Glioma. Front Oncol 2020;10:508. [PMID: 32373523 DOI: 10.3389/fonc.2020.00508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
639 Witte KE, Hertel O, Windmöller BA, Helweg LP, Höving AL, Knabbe C, Busche T, Greiner JFW, Kalinowski J, Noll T, Mertzlufft F, Beshay M, Pfitzenmaier J, Kaltschmidt B, Kaltschmidt C, Banz-Jansen C, Simon M. Nanopore Sequencing Reveals Global Transcriptome Signatures of Mitochondrial and Ribosomal Gene Expressions in Various Human Cancer Stem-like Cell Populations. Cancers (Basel) 2021;13:1136. [PMID: 33800955 DOI: 10.3390/cancers13051136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
640 Lai IC, Shih PH, Yao CJ, Yeh CT, Wang-Peng J, Lui TN, Chuang SE, Hu TS, Lai TY, Lai GM. Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells. PLoS One 2015;10:e0114830. [PMID: 25763821 DOI: 10.1371/journal.pone.0114830] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
641 Calabrese E, Villanueva-Meyer JE, Cha S. A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas. Sci Rep 2020;10:11852. [PMID: 32678261 DOI: 10.1038/s41598-020-68857-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
642 Lindholm DP, Eriksson B, Granberg D. Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma. Med Oncol 2012;29:301-3. [PMID: 21191667 DOI: 10.1007/s12032-010-9789-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
643 Hempel JM, Brendle C, Bender B, Bier G, Skardelly M, Gepfner-Tuma I, Eckert F, Ernemann U, Schittenhelm J. Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study. J Neurooncol 2018;139:373-81. [PMID: 29667086 DOI: 10.1007/s11060-018-2872-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
644 Frandsen S, Broholm H, Larsen VA, Grunnet K, Møller S, Poulsen HS, Michaelsen SR. Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma. Front Oncol 2019;9:1425. [PMID: 31921679 DOI: 10.3389/fonc.2019.01425] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
645 Skinner KR, Nabors LB, Miller CR. Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics. Neuro Oncol 2020;22:1713-4. [PMID: 33257985 DOI: 10.1093/neuonc/noaa242] [Reference Citation Analysis]
646 Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 2008;87:71-8. [PMID: 18004504 DOI: 10.1007/s11060-007-9486-0] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 4.6] [Reference Citation Analysis]
647 Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, Seyfried TN. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond) 2010;7:33. [PMID: 20412570 DOI: 10.1186/1743-7075-7-33] [Cited by in Crossref: 156] [Cited by in F6Publishing: 139] [Article Influence: 13.0] [Reference Citation Analysis]
648 Eom KY, Cho BJ, Choi EJ, Kim JH, Chie EK, Wu HG, Kim IH, Paek SH, Kim JS, Kim IA. The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo. Cancer Res Treat 2016;48:687-97. [PMID: 26044161 DOI: 10.4143/crt.2014.320] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
649 Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006;8:209-217. [PMID: 16645207 DOI: 10.2353/jmoldx.2006.050135] [Cited by in Crossref: 301] [Cited by in F6Publishing: 316] [Article Influence: 18.8] [Reference Citation Analysis]
650 Newton HB. Glioblastoma multiforme. Curr Treat Options Neurol 2008;10:285-94. [PMID: 18579015 DOI: 10.1007/s11940-008-0031-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
651 Shim H, Wei L, Holder CA, Guo Y, Hu XP, Miller AH, Olson JJ. Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor. AJR Am J Roentgenol 2014;203:W158-65. [PMID: 25055291 DOI: 10.2214/AJR.14.12518] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
652 Kazim SF, Martinez E, Hough TJ, Spangler BQ, Bowers CA, Chohan MO. The Survival Benefit of Postoperative Bacterial Infections in Patients With Glioblastoma Multiforme: Myth or Reality? Front Neurol 2021;12:615593. [PMID: 33613432 DOI: 10.3389/fneur.2021.615593] [Reference Citation Analysis]
653 Tabouret E, Tassy L, Chinot O, Crétel E, Retornaz F, Rousseau F. High-grade glioma in elderly patients: can the oncogeriatrician help? Clin Interv Aging 2013;8:1617-24. [PMID: 24353408 DOI: 10.2147/CIA.S35941] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
654 Erbayraktar Z, Alural B, Erbayraktar RS, Erkan EP. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int 2016;16:88. [PMID: 27891063 DOI: 10.1186/s12935-016-0364-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
655 Ellingson BM. Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. Curr Neurol Neurosci Rep 2015;15:506. [PMID: 25410316 DOI: 10.1007/s11910-014-0506-0] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 12.7] [Reference Citation Analysis]
656 Lange F, Hörnschemeyer J, Kirschstein T. Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Cells 2021;10:1226. [PMID: 34067762 DOI: 10.3390/cells10051226] [Reference Citation Analysis]
657 Tsai HC, Wei KC, Chen PY, Huang CY, Chen KT, Lin YJ, Cheng HW, Chen YR, Wang HT. Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway. Front Oncol 2021;11:722754. [PMID: 34660288 DOI: 10.3389/fonc.2021.722754] [Reference Citation Analysis]
658 Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol 2015;17:1148-56. [PMID: 25646027 DOI: 10.1093/neuonc/nou364] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
659 Rabab'h O, Al-Ramadan A, Shah J, Lopez-Negrete H, Gharaibeh A. Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival. Cureus 2021;13:e16061. [PMID: 34345547 DOI: 10.7759/cureus.16061] [Reference Citation Analysis]
660 Mirimanoff RO. High-grade gliomas: reality and hopes. Chin J Cancer 2014;33:1-3. [PMID: 24384235 DOI: 10.5732/cjc.013.10215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
661 Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012;118:5601-7. [PMID: 22517399 DOI: 10.1002/cncr.27585] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 8.5] [Reference Citation Analysis]
662 Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. AJNR Am J Neuroradiol 2016;37:2201-8. [PMID: 27492073 DOI: 10.3174/ajnr.A4898] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
663 Alnahhas I, Rayi A, Guillermo Prieto Eibl MDP, Ong S, Giglio P, Puduvalli V. Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDHwt glioblastoma. Neurooncol Adv 2021;3:vdab127. [PMID: 34667950 DOI: 10.1093/noajnl/vdab127] [Reference Citation Analysis]
664 Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769-1792. [PMID: 25198391 DOI: 10.3390/cancers6031769] [Cited by in Crossref: 995] [Cited by in F6Publishing: 892] [Article Influence: 124.4] [Reference Citation Analysis]
665 Batich KA, Sampson JH. Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opin Pharmacother 2014;15:2047-61. [PMID: 25139628 DOI: 10.1517/14656566.2014.947266] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
666 Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, Hamilton RL, Banze LA, Brown AR, Sobol RW. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol 2011;13:471-86. [PMID: 21377995 DOI: 10.1093/neuonc/nor011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
667 Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 2014;9:357-67. [PMID: 24591820 DOI: 10.2147/CIA.S44259] [Cited by in Crossref: 18] [Cited by in F6Publishing: 47] [Article Influence: 2.3] [Reference Citation Analysis]
668 Johanns TM, Miller CA, Liu CJ, Perrin RJ, Bender D, Kobayashi DK, Campian JL, Chicoine MR, Dacey RG, Huang J, Fritsch EF, Gillanders WE, Artyomov MN, Mardis ER, Schreiber RD, Dunn GP. Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. Oncoimmunology 2019;8:e1561106. [PMID: 30906654 DOI: 10.1080/2162402X.2018.1561106] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
669 Jiang H, Yu K, Cui Y, Ren X, Li M, Zhang G, Yang C, Zhao X, Zhu Q, Lin S. Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma. Front Oncol 2021;11:632663. [PMID: 34055603 DOI: 10.3389/fonc.2021.632663] [Reference Citation Analysis]
670 Kessler T, Berberich A, Casalini B, Drüschler K, Ostermann H, Dormann A, Walter S, Hai L, Schlesner M, Herold-Mende C, Jungk C, Unterberg A, Bendszus M, Sahm K, von Deimling A, Winkler F, Platten M, Wick W, Sahm F, Wick A. Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neurooncol Adv 2020;2:vdz060. [PMID: 32642725 DOI: 10.1093/noajnl/vdz060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
671 Shirazi HA, Grimm S, Raizer J, Mehta MP. Combined modality approaches in the management of adult glioblastoma. Front Oncol 2011;1:36. [PMID: 22655242 DOI: 10.3389/fonc.2011.00036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
672 Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanov